BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047. [PMID: 10744089 DOI: 10.1016/s0140-6736(00)02034-1] [Cited by in Crossref: 2374] [Cited by in F6Publishing: 2583] [Article Influence: 103.2] [Reference Citation Analysis]
Number Citing Articles
1 Ohishi T, Kaneko MK, Yoshida Y, Takashima A, Kato Y, Kawada M. Current Targeted Therapy for Metastatic Colorectal Cancer. Int J Mol Sci 2023;24. [PMID: 36675216 DOI: 10.3390/ijms24021702] [Reference Citation Analysis]
2 Pécsi B, Mangel L. Real-Life Effectivity of Dose Intensity Reduction of First-Line mFOLFIRI-Based Treatment of Metastatic Colorectal Cancers: Sometimes Less Is More. Curr Oncol 2023;30:908-22. [PMID: 36661718 DOI: 10.3390/curroncol30010069] [Reference Citation Analysis]
3 Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34:10-32. [PMID: 36307056 DOI: 10.1016/j.annonc.2022.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Fang Q, Lin J, Gao L, Pan R, Zheng X. Targeting mitochondrial tyrosyl-tRNA synthetase YARS2 suppresses colorectal cancer progression. Cancer Biol Ther 2022;23:1-8. [PMID: 36154909 DOI: 10.1080/15384047.2022.2127603] [Reference Citation Analysis]
5 Yang X, Xia X, Huang W, Xia X, Yan D. Highly efficient tumor-targeted nanomedicine assembled from affibody-drug conjugate for colorectal cancer therapy. Nano Res 2022. [DOI: 10.1007/s12274-022-5183-8] [Reference Citation Analysis]
6 Zaher NH, El-hazek RMM, Emam HES, El-gazzar MG, Khalil A. Pyrazole-sulfonamide scaffold featuring dual-tail strategy as apoptosis inducers in colon cancer. Design, synthesis, biological, and docking studies.. [DOI: 10.21203/rs.3.rs-2394883/v1] [Reference Citation Analysis]
7 Park SY, Park JS, Kim HJ, Kim JG, Kang BW, Baek JH, Kim HR, Kim CH, Kim YJ, Choi G. Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi‐institutional retrospective analysis. Journal of Surgical Oncology 2022. [DOI: 10.1002/jso.27171] [Reference Citation Analysis]
8 Huang M, Huang Y, Cheng T, Jhang W, Ke CC, Chen Y, Kuo S, Lin I, Huang Y, Chuang C. XPF-ERCC1 blocker improves the therapeutic efficacy of 5-FU- and oxaliplatin-based chemoradiotherapy in rectal cancer.. [DOI: 10.21203/rs.3.rs-2236583/v1] [Reference Citation Analysis]
9 Islam MR, Akash S, Rahman MM, Nowrin FT, Akter T, Shohag S, Rauf A, Aljohani AS, Simal-gandara J. Colon cancer and colorectal cancer: Prevention and treatment by potential natural products. Chemico-Biological Interactions 2022;368:110170. [DOI: 10.1016/j.cbi.2022.110170] [Reference Citation Analysis]
10 Wu P, Pan X, Lu K, Gu N. Screening prognostic genes related to leucovorin, fluorouracil, and irinotecan treatment sensitivity by performing co-expression network analysis for colon cancer. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.928356] [Reference Citation Analysis]
11 Su YT, Chen JW, Chang SC, Jiang JK, Huang SC. The clinical experience of the prognosis in opposite CEA and image change after therapy in stage IV colorectal cancer. Sci Rep 2022;12:20075. [PMID: 36418865 DOI: 10.1038/s41598-022-24187-5] [Reference Citation Analysis]
12 Hong X, Yu T, Huang X, Wang J, Sun T, Yan T, Zhou C, Chen H, Su W, Du W, Xiong H. Metformin abrogates Fusobacterium nucleatum-induced chemoresistance in colorectal cancer by inhibiting miR-361-5p/sonic hedgehog signaling-regulated stemness. Br J Cancer 2022. [DOI: 10.1038/s41416-022-02044-6] [Reference Citation Analysis]
13 Kroupová J, Hanuš J, Štěpánek F. Surprising efficacy twist of two established cytostatics revealed by a-la-carte 3D cell spheroid preparation protocol. European Journal of Pharmaceutics and Biopharmaceutics 2022;180:224-237. [DOI: 10.1016/j.ejpb.2022.10.003] [Reference Citation Analysis]
14 Ludikhuize MC, Gevers S, Nguyen NTB, Meerlo M, Roudbari SKS, Gulersonmez MC, Stigter ECA, Drost J, Clevers H, Burgering BMT, Rodríguez Colman MJ. Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRASG12D glycolytic colorectal tumors. Commun Biol 2022;5:1159. [PMID: 36316440 DOI: 10.1038/s42003-022-04055-8] [Reference Citation Analysis]
15 Kanesada K, Tsunedomi R, Hazama S, Ogihara H, Hamamoto Y, Shindo Y, Matsui H, Tokumitsu Y, Yoshida S, Iida M, Suzuki N, Takeda S, Ioka T, Nagano H. Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer Medicine 2022. [DOI: 10.1002/cam4.5299] [Reference Citation Analysis]
16 Meng G, Yang S, Chen F. Survival for patients with metastatic colon cancer underwent cytoreductive colectomy in the era of rapid development of anticancer drugs: A real-world analysis based on updated population dataset of 2004–2018. Front Pharmacol 2022;13:983092. [DOI: 10.3389/fphar.2022.983092] [Reference Citation Analysis]
17 Jang HR, Lee HY, Song SY, Lim KH. Clinical outcomes of targeted therapies in elderly patients aged ≥ 80 years with metastatic colorectal cancer. World J Clin Cases 2022; 10(28): 10066-10076 [DOI: 10.12998/wjcc.v10.i28.10066] [Reference Citation Analysis]
18 Carlsson G, Koumarianou A, Guren T, Haux J, Katsaounis P, Kentepozidis N, Pfeiffer P, Brændengen M, Mavroudis D, Taflin H, Skintemo L, Tell R, Papadimitriou C. A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer. ESMO Open 2022;7:100589. [DOI: 10.1016/j.esmoop.2022.100589] [Reference Citation Analysis]
19 Liu W, Chen FL, Wang K, Bao Q, Wang HW, Jin KM, Xing BC. Irinotecan- vs oxaliplatin-based regimens for neoadjuvant chemotherapy in colorectal liver metastasis patients: A retrospective study. World J Gastrointest Surg 2022; 14(9): 904-917 [DOI: 10.4240/wjgs.v14.i9.904] [Reference Citation Analysis]
20 Lv L, Shen X, Zhang J, Li Q, Wu J, Wu Y, Chen J, Zhu W, Zheng L. Clinical Observation of Fuzheng Xiaoji Granule in the Treatment of Stage IIIC Colorectal Cancer. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-8. [DOI: 10.1155/2022/4618342] [Reference Citation Analysis]
21 Riesco-Martinez MC, Modrego A, Espinosa-Olarte P, La Salvia A, Garcia-Carbonero R. Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer: Lessons Learned and Future Perspectives. Curr Treat Options Oncol 2022. [PMID: 35980520 DOI: 10.1007/s11864-022-01008-5] [Reference Citation Analysis]
22 Sasaki A, Sakata K, Nakano K, Tsutsumi S, Fujishima H, Futsukaichi T, Terashi T, Ikebe M, Bandoh T, Utsunomiya T. Prognostic significance of intrahepatic lymphatic invasion in colorectal liver metastases. Ann Diagn Pathol 2022;60:152026. [PMID: 35988375 DOI: 10.1016/j.anndiagpath.2022.152026] [Reference Citation Analysis]
23 Zhang Q, Deng T, Yang F, Guo W, Liu D, Yuan J, Qi C, Cao Y, Yu Q, Cai H, Peng Z, Wang X, Zhou J, Lu M, Gong J, Li J, Ba Y, Shen L. A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor. Front Pharmacol 2022;13:833583. [DOI: 10.3389/fphar.2022.833583] [Reference Citation Analysis]
24 Geertsen Keller J, Vandsø Petersen K, R. Knudsen B, Tesauro C. Simple and Fast DNA-Based Tool to Investigate Topoisomerase 1 Activity, a Biomarker for Drug Susceptibility in Colorectal Cancer. Recent Understanding of Colorectal Cancer Treatment [Working Title] 2022. [DOI: 10.5772/intechopen.105758] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Kryczka J, Boncela J. Integrated Bioinformatics Analysis of the Hub Genes Involved in Irinotecan Resistance in Colorectal Cancer. Biomedicines 2022;10:1720. [DOI: 10.3390/biomedicines10071720] [Reference Citation Analysis]
26 Pelullo M, Zema S, De Carolis M, Cialfi S, Giuli MV, Palermo R, Capalbo C, Giannini G, Screpanti I, Checquolo S, Bellavia D. 5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance. Front Oncol 2022;12:918763. [DOI: 10.3389/fonc.2022.918763] [Reference Citation Analysis]
27 Nixon AB, Sibley AB, Liu Y, Hatch AJ, Jiang C, Mulkey F, Starr MD, Brady JC, Niedzwiecki D, Venook AP, Baez-Diaz L, Lenz HJ, O'Neil BH, Innocenti F, Meyerhardt JA, O'Reilly EM, Owzar K, Hurwitz HI. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). Clin Cancer Res 2022;28:2779-88. [PMID: 34965954 DOI: 10.1158/1078-0432.CCR-21-2389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
28 Castellani G, Buccarelli M, Lulli V, Ilari R, De Luca G, Pedini F, Boe A, Felli N, Biffoni M, Pilozzi E, Marziali G, Ricci-vitiani L. MiR-378a-3p Acts as a Tumor Suppressor in Colorectal Cancer Stem-Like Cells and Affects the Expression of MALAT1 and NEAT1 lncRNAs. Front Oncol 2022;12:867886. [DOI: 10.3389/fonc.2022.867886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhao L, Zhao H, Zhao Y, Sui M, Liu J, Li P, Liu N, Zhang K. Role of Ginseng, Quercetin, and Tea in Enhancing Chemotherapeutic Efficacy of Colorectal Cancer. Front Med 2022;9:939424. [DOI: 10.3389/fmed.2022.939424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Huang X, Ke K, Jin W, Zhu Q, Zhu Q, Mei R, Zhang R, Yu S, Shou L, Sun X, Feng J, Duan T, Mou Y, Xie T, Wu Q, Sui X. Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. Front Immunol 2022;13:887048. [DOI: 10.3389/fimmu.2022.887048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Greenberg I, Sokol E, Goldberg AK, Simkin D, Benhamou M, Bar-shira S, Raz M, Grossman R, Yeini E, Ofek P, Liang B, Satchi-fainaro R, Reuveni H, Rubinek T, Wolf I. Genomic alterations drive brain metastases formation in colorectal cancer: The role of IRS2.. [DOI: 10.1101/2022.06.10.495658] [Reference Citation Analysis]
32 Chou J, Kaller M, Jaeckel S, Rokavec M, Hermeking H. AP4 suppresses DNA damage, chromosomal instability and senescence via inducing MDC1/Mediator of DNA damage Checkpoint 1 and repressing MIR22HG/miR-22-3p. Mol Cancer 2022;21:120. [PMID: 35624466 DOI: 10.1186/s12943-022-01581-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Gallois C, Hafliger E, Auclin E, Perret A, Coutzac C, Turpin A, Pellat A, Randrian V, Basile D, Faroux R, Pernot S, Locher C, Hautefeuille V, Dubreuil O, Palmieri LJ, Dior M, Artru P, Taieb J. First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study. Dig Liver Dis 2022;54:684-91. [PMID: 34470724 DOI: 10.1016/j.dld.2021.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Artale S, Grillo N, Lepori S, Butti C, Bovio A, Barzaghi S, Colombo A, Castiglioni E, Barbarini L, Zanlorenzi L, Antonelli P, Caccialanza R, Pedrazzoli P, Moroni M, Basciani S, Azzarello R, Serra F, Trojani A. A Nutritional Approach for the Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer. Nutrients 2022;14:1801. [PMID: 35565769 DOI: 10.3390/nu14091801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Chen L, Tian B, Liu W, Liang H, You Y, Liu W. Molecular Biomarker of Drug Resistance Developed From Patient-Derived Organoids Predicts Survival of Colorectal Cancer Patients. Front Oncol 2022;12:855674. [PMID: 35425715 DOI: 10.3389/fonc.2022.855674] [Reference Citation Analysis]
36 Qu Y, Liu X, Zhao S, Zhai X. SPOCK1 silencing decreases 5-FU resistance through PRRX1 in colorectal cancer. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153895] [Reference Citation Analysis]
37 Thompson LL, Rutherford KA, Lepage CC, McManus KJ. Aberrant SKP1 Expression: Diverse Mechanisms Impacting Genome and Chromosome Stability. Front Cell Dev Biol 2022;10:859582. [PMID: 35345853 DOI: 10.3389/fcell.2022.859582] [Reference Citation Analysis]
38 Zhang W, Kong L, Zhu H, Sun D, Han Q, Yan B, Cui Z, Zhang W, Zhang S, Kang X, Dai G, Qian N, Yan W. Retinoic Acid-Induced 2 (RAI2) Is a Novel Antagonist of Wnt/β-Catenin Signaling Pathway and Potential Biomarker of Chemosensitivity in Colorectal Cancer. Front Oncol 2022;12:805290. [PMID: 35299743 DOI: 10.3389/fonc.2022.805290] [Reference Citation Analysis]
39 Khaliq R, Iqbal P, Wani AY. Colorectal Cancer. Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics 2022. [DOI: 10.4018/978-1-7998-9258-8.ch006] [Reference Citation Analysis]
40 Oteyola AO, Pilla R, Ola-oladimeji FA, Fagbuaro O. Natural Products Application and Combination Therapy in Colorectal Cancer Treatment. Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics 2022. [DOI: 10.4018/978-1-7998-9258-8.ch004] [Reference Citation Analysis]
41 Reyes JM. Medicina de precisión en cáncer colorrectal y gastroesofágico avanzado. Revista Médica Clínica Las Condes 2022;33:125-39. [DOI: 10.1016/j.rmclc.2022.03.003] [Reference Citation Analysis]
42 Kawaguchi Y, Kopetz S, Panettieri E, Hwang H, Wang X, Cao HST, Tzeng CD, Chun YS, Aloia TA, Vauthey JN. Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer. J Gastrointest Surg 2022;26:583-93. [PMID: 34506029 DOI: 10.1007/s11605-021-05110-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
43 Kawakami T, Masuishi T, Kawamoto Y, Go H, Kato K, Kumanishi R, Sawada K, Yuki S, Yamamoto K, Komatsu Y, Muro K, Fushiki K, Shirasu H, Yamazaki K. The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. Cancer Med 2022. [PMID: 35182029 DOI: 10.1002/cam4.4599] [Reference Citation Analysis]
44 Temraz S, Nasr F, Kattan J, Abigerges D, Moukadem W, Farhat F, Maatouk L, Chahine G, Shamseddine A. A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon. BTT 2022;Volume 16:7-15. [DOI: 10.2147/btt.s340525] [Reference Citation Analysis]
45 Moosavy SH, Koochakkhani S, Barazesh M, Mohammadi S, Ahmadi K, Inchehsablagh BR, Kavousipour S, Eftekhar E, Mokaram P. In silico Analysis of Single Nucleotide Polymorphisms Associated with MicroRNA Regulating 5-fluorouracil Resistance in Colorectal Cancer. LDDD 2022;19:144-159. [DOI: 10.2174/1570180818666210930161618] [Reference Citation Analysis]
46 Chang T, Chuang K, Chang Y. Ag/Ga-doped ZnO/pyramidal silicon as a multifunctional surface-enhanced Raman scattering substrate. Journal of Alloys and Compounds 2022;893:162288. [DOI: 10.1016/j.jallcom.2021.162288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022;14:175883592110727. [DOI: 10.1177/17588359211072703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Gelli M, Adam R. Liver Transplantation for Colorectal Cancer Liver Metastases. Textbook of Liver Transplantation 2022. [DOI: 10.1007/978-3-030-82930-8_41] [Reference Citation Analysis]
49 Daemen A, Udyavar AR, Sandmann T, Li C, Bosch LJW, O'Gorman W, Li Y, Au-Yeung A, Takahashi C, Kabbarah O, Bourgon R, Hegde P, Bais C, Das Thakur M. Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B. PLoS One 2021;16:e0262198. [PMID: 34972191 DOI: 10.1371/journal.pone.0262198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Verma HK, Ratre YK, Mazzone P. Chemoresistance in Colorectal Malignancies: Molecular Mechanisms and Strategies to Overcome. Colon Cancer Diagnosis and Therapy Vol. 3 2022. [DOI: 10.1007/978-3-030-72702-4_7] [Reference Citation Analysis]
51 Yu IS, Advani S, Kopetz S. Initial Systemic Chemotherapy for Metastatic Colorectal Cancer. Colorectal Liver Metastasis 2022. [DOI: 10.1007/978-3-031-09323-4_31] [Reference Citation Analysis]
52 Wang Z, Yang B. Polypharmacology in Clinical Applications—Anticancer Polypharmacology. Polypharmacology 2022. [DOI: 10.1007/978-3-031-04998-9_3] [Reference Citation Analysis]
53 Liu L, Xiang Z. Adjuvant chemotherapy improves survival in high-risk stage II colon cancer: a retrospective cohort study. Therap Adv Gastroenterol 2022;15:175628482211377. [DOI: 10.1177/17562848221137758] [Reference Citation Analysis]
54 Hadjittofi C, Feretis M, Martin J, Harper S, Huguet E. Liver regeneration biology: Implications for liver tumour therapies. World J Clin Oncol 2021; 12(12): 1101-1156 [DOI: 10.5306/wjco.v12.i12.1101] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Sahebi U, Gholami H, Ghalandari B, Badalkhani-khamseh F, Nikzamir A, Divsalar A. Evaluation of BLG ability for binding to 5-FU and Irinotecan simultaneously under acidic condition: A spectroscopic, molecular docking and molecular dynamic simulation study. Journal of Molecular Liquids 2021;344:117758. [DOI: 10.1016/j.molliq.2021.117758] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Dandash F, Leger DY, Diab-Assaf M, Sol V, Liagre B. Porphyrin/Chlorin Derivatives as Promising Molecules for Therapy of Colorectal Cancer. Molecules 2021;26:7268. [PMID: 34885849 DOI: 10.3390/molecules26237268] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Wang J, Zhang X, Zhang J, Chen S, Zhu J, Wang X. Long noncoding RNA CRART16 confers 5-FU resistance in colorectal cancer cells by sponging miR-193b-5p. Cancer Cell Int 2021;21:638. [PMID: 34844630 DOI: 10.1186/s12935-021-02353-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Ludikhuize MC, Gevers S, Nguyen NT, Meerlo M, Shafiei Roudbari SK, Gulersonmez MC, Stigter EC, Drost J, Clevers H, Burgering BM, Rodríguez Colman MJ. Rewiring glucose metabolism improves 5-FU efficacy in glycolytic p53-deficient colorectal tumors.. [DOI: 10.1101/2021.11.11.468185] [Reference Citation Analysis]
59 Cesmeli S, Goker Bagca B, Caglar HO, Ozates NP, Gunduz C, Biray Avci C. Combination of resveratrol and BIBR1532 inhibits proliferation of colon cancer cells by repressing expression of LncRNAs. Med Oncol 2021;39:12. [PMID: 34779924 DOI: 10.1007/s12032-021-01611-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
60 Yeoh Y, Low TY, Abu N, Lee PY. Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. PeerJ 2021;9:e12338. [PMID: 34733591 DOI: 10.7717/peerj.12338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Tamura A, Ishida K, Sone M, Yoshioka K. Evaluation of peripheral enhancement on contrast-enhanced CT and corresponding pathological findings in colorectal liver metastases after preoperative chemotherapy.. [DOI: 10.1101/2021.10.27.21265582] [Reference Citation Analysis]
62 Kamo M, Kochi M, Okamura Y. Complete Remission of Unresectable Rectal CancerFollowing FOLFOXIRI and Cetuximab Treatment. Nichidai Igaku Zasshi 2021;80:259-262. [DOI: 10.4264/numa.80.5_259] [Reference Citation Analysis]
63 Wagner S, Beger NT, Matschos S, Szymanski A, Przybylla R, Bürtin F, Prall F, Linnebacher M, Mullins CS. Tumour-Derived Cell Lines and Their Potential for Therapy Prediction in Patients with Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:4717. [PMID: 34572946 DOI: 10.3390/cancers13184717] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Tharin Z, Blanc J, Alaoui IC, Bertaut A, Ghiringhelli F. Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer. J Gastrointest Oncol 2021;12:1509-17. [PMID: 34532106 DOI: 10.21037/jgo-20-593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
65 Siri M, Behrouj H, Dastghaib S, Zamani M, Likus W, Rezaie S, Hudecki J, Khazayel S, Łos MJ, Mokarram P, Ghavami S. Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition. Arch Immunol Ther Exp (Warsz) 2021;69:26. [PMID: 34536148 DOI: 10.1007/s00005-021-00629-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
66 Sarkar P, Samanta A, Maity TR, Datta S. Evaluation of the effects of 5-fluorouracil and cyclophosphamide on Lathyrus sativus L. Bull Natl Res Cent 2021;45. [DOI: 10.1186/s42269-021-00611-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Beklen H, Arslan S, Gulfidan G, Turanli B, Ozbek P, Karademir Yilmaz B, Arga KY. Differential Interactome Based Drug Repositioning Unraveled Abacavir, Exemestane, Nortriptyline Hydrochloride, and Tolcapone as Potential Therapeutics for Colorectal Cancers. Front Bioinform 2021;1. [DOI: 10.3389/fbinf.2021.710591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Degeling K, Wong HL, Koffijberg H, Jalali A, Shapiro J, Kosmider S, Wong R, Lee B, Burge M, Tie J, Yip D, Nott L, Khattak A, Lim S, Caird S, Gibbs P, IJzerman M. Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. Pharmacoeconomics 2020;38:1263-75. [PMID: 32803720 DOI: 10.1007/s40273-020-00951-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
69 Samare-najaf M, Samareh A, Jamali N, Abbasi A, Clark CC, Khorchani MJ, Zal F. Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review. CCTR 2021;17:234-43. [DOI: 10.2174/1573394717666210202103502] [Reference Citation Analysis]
70 Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol 2021;11:688377. [PMID: 34336673 DOI: 10.3389/fonc.2021.688377] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
71 Sharma P, Shimura T, Banwait JK, Goel A. Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer. Carcinogenesis 2020;41:1385-94. [PMID: 32835374 DOI: 10.1093/carcin/bgaa090] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
72 Wang T, Pan W, Zheng H, Zheng H, Wang Z, Li JJ, Deng C, Yan J. Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer: A Blinded Study. Dis Colon Rectum 2021;64:833-50. [PMID: 33709991 DOI: 10.1097/DCR.0000000000001971] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
73 Zulkifli A, Tan FH, Areeb Z, Stuart SF, Gomez J, Paradiso L, Luwor RB. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer. Int J Mol Sci 2021;22:7114. [PMID: 34281166 DOI: 10.3390/ijms22137114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T. Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. Front Oncol 2021;11:688709. [PMID: 34211856 DOI: 10.3389/fonc.2021.688709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 PelvEx Collaborative . Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). BJS Open 2021;5:zrab029. [PMID: 34089596 DOI: 10.1093/bjsopen/zrab029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Yuan M, Wang Z, Zhao Y, Feng T, Lv W, Zhong H. Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital. Front Pharmacol 2021;12:632076. [PMID: 34122063 DOI: 10.3389/fphar.2021.632076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Budithi A, Su S, Kirshtein A, Shahriyari L. Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. Cancers (Basel) 2021;13:2632. [PMID: 34071939 DOI: 10.3390/cancers13112632] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
78 Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers (Basel) 2021;13:2296. [PMID: 34064974 DOI: 10.3390/cancers13102296] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
79 Guan Y, Fan P, Dong W, Shang D. A covalent triazine-based framework containing hydrogen-bonding for highly drug loading and pH-responsive release. Journal of Macromolecular Science, Part A 2021;58:630-5. [DOI: 10.1080/10601325.2021.1922085] [Reference Citation Analysis]
80 Schulte B, Benson AB. Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer. Advances in Oncology 2021;1:297-310. [DOI: 10.1016/j.yao.2021.02.025] [Reference Citation Analysis]
81 Li J, Zhou L, Liu Y, Yang L, Jiang D, Li K, Xie S, Wang X, Wang S. Comprehensive Analysis of Cyclin Family Gene Expression in Colon Cancer. Front Oncol 2021;11:674394. [PMID: 33996604 DOI: 10.3389/fonc.2021.674394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
82 Yun CW, Lee JH, Go G, Jeon J, Yoon S, Lee SH. Prion Protein of Extracellular Vesicle Regulates the Progression of Colorectal Cancer. Cancers (Basel) 2021;13:2144. [PMID: 33946823 DOI: 10.3390/cancers13092144] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
83 Chida K, Kotani D, Nakamura Y, Kawazoe A, Kuboki Y, Shitara K, Kojima T, Taniguchi H, Watanabe J, Endo I, Yoshino T. Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. Ther Adv Med Oncol 2021;13:17588359211009143. [PMID: 33959196 DOI: 10.1177/17588359211009143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Anselmino LE, Baglioni MV, Malizia F, Laluce NC, Etichetti CB, Marignac VLM, Rozados V, Scharovsky OG, Girardini J, Rico MJ, Menacho Márquez M. Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment. Sci Rep 2021;11:8091. [PMID: 33854147 DOI: 10.1038/s41598-021-87525-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
85 Wang Y, Wei Q, Chen Y, Long S, Yao Y, Fu K. Identification of Hub Genes Associated With Sensitivity of 5-Fluorouracil Based Chemotherapy for Colorectal Cancer by Integrated Bioinformatics Analysis. Front Oncol 2021;11:604315. [PMID: 33912443 DOI: 10.3389/fonc.2021.604315] [Reference Citation Analysis]
86 Wang DS, Hu MT, Wang ZQ, Ren C, Qiu MZ, Luo HY, Jin Y, Fong WP, Wang SB, Peng JW, Zou QF, Tan Q, Wang FH, Li YH. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. JAMA Netw Open 2021;4:e215250. [PMID: 33835174 DOI: 10.1001/jamanetworkopen.2021.5250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
87 Qutub RM, Al-Ghafari AB, Al Doghaither HA, Omar UM, Ghulam JM. Increased expressions of cellular ATP-binding cassette transporters may be a promising diagnostic marker for colorectal cancer. Saudi Med J 2020;41:834-40. [PMID: 32789424 DOI: 10.15537/smj.2020.8.25187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okita Y, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Shimada Y. Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). Front Oncol 2021;11:576036. [PMID: 33763345 DOI: 10.3389/fonc.2021.576036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Herbrand AK, Schmitt AM, Briel M, Ewald H, Goldkuhle M, Diem S, Hoogkamer A, Joerger M, Moffa G, Novak U, Hemkens LG, Kasenda B. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA Netw Open 2021;4:e210380. [PMID: 33651108 DOI: 10.1001/jamanetworkopen.2021.0380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
90 Tian J, Zhang D, Kurbatov V, Wang Q, Wang Y, Fang D, Wu L, Bosenberg M, Muzumdar MD, Khan S, Lu Q, Yan Q, Lu J. 5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING. EMBO J 2021;40:e106065. [PMID: 33615517 DOI: 10.15252/embj.2020106065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
91 Eng C. BRAF Mutation in Colorectal Cancer: An Enigmatic Target. J Clin Oncol 2021;39:259-61. [PMID: 33503394 DOI: 10.1200/JCO.20.03043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
92 Vaugier L, Mirabel X, Martel-Lafay I, Racadot S, Carrie C, Vendrely V, Mahé MA, Senellart H, Raoul JL, Campion L, Rio E. Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer. Cancers (Basel) 2021;13:E248. [PMID: 33440832 DOI: 10.3390/cancers13020248] [Reference Citation Analysis]
93 Reidy E, Leonard NA, Treacy O, Ryan AE. A 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance. Cancers (Basel) 2021;13:E227. [PMID: 33435170 DOI: 10.3390/cancers13020227] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
94 Ahmad R, Singh JK, Wunnava A, Al-Obeed O, Abdulla M, Srivastava SK. Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review). Int J Mol Med. 2021;47. [PMID: 33655327 DOI: 10.3892/ijmm.2021.4847] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
95 Moorkoth D, Nampoothiri KM, Nagarajan S, Ravindran Girija A, Balasubramaniyan S, Kumar DS. Star-Shaped Polylactide Dipyridamole Conjugated to 5-Fluorouracil and 4-Piperidinopiperidine Nanocarriers for Bioimaging and Dual Drug Delivery in Cancer Cells. ACS Appl Polym Mater 2021;3:737-56. [DOI: 10.1021/acsapm.0c01043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
96 Kørner H, Søreide JA. Surgical Treatment in Palliative Care. Multidisciplinary Treatment of Colorectal Cancer 2021. [DOI: 10.1007/978-3-030-58846-5_33] [Reference Citation Analysis]
97 Pfeiffer P, Qvortrup C. Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer. Multidisciplinary Treatment of Colorectal Cancer 2021. [DOI: 10.1007/978-3-030-58846-5_21] [Reference Citation Analysis]
98 Tsunedomi R. Rapid and Sensitive Detection of UGT1A1 Polymorphisms Associated with Irinotecan Toxicity by a Novel DNA Microarray. Yamaguchi Medical Journal 2020;69:161-168. [DOI: 10.2342/ymj.69.161] [Reference Citation Analysis]
99 Cecchini M, Kortmansky JS, Cui C, Wei W, Thumar JR, Uboha NV, Hafez N, Lacy J, Fischbach NA, Sabbath KD, Gomez CM, Sporn JR, Stein S, Hochster HS. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer 2021;127:1417-24. [PMID: 33351187 DOI: 10.1002/cncr.33379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
100 Kononenko IB, Snegovoy AV, Grebennikova OP, Sel’chuk VY, Palchinskaia OV. Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy. J Mod Onco 2020;22:133-141. [DOI: 10.26442/18151434.2020.3.200279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
101 Nozawa H, Emoto S, Murono K, Shuno Y, Kawai K, Sasaki K, Sonoda H, Ishii H, Iida Y, Yokoyama Y, Anzai H, Ishihara S. Change in skeletal muscle index and its prognostic significance in patients who underwent successful conversion therapy for initially unresectable colorectal cancer: observational study. Therap Adv Gastroenterol 2020;13:1756284820971197. [PMID: 33240393 DOI: 10.1177/1756284820971197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Blazevic I, Vaillant W, Basso M, Salignon K. Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer. Contemp Oncol (Pozn) 2020;24:150-6. [PMID: 33235540 DOI: 10.5114/wo.2020.100222] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Alonso S, Saltz L. The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer. Ann Surg Oncol 2021;28:995-1001. [PMID: 33230749 DOI: 10.1245/s10434-020-09375-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
104 Simões AR, Fernández-Rozadilla C, Maroñas O, Carracedo Á. The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment? J Pers Med 2020;10:E237. [PMID: 33228198 DOI: 10.3390/jpm10040237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
105 Li Y, Guo D, Zhang Y, Wang L, Sun T, Li Z, Zhang X, Wang S, Chen Y, Wu A. Rapid screening for individualized chemotherapy optimization of colorectal cancer: A novel conditional reprogramming technology-based functional diagnostic assay. Transl Oncol 2021;14:100935. [PMID: 33190042 DOI: 10.1016/j.tranon.2020.100935] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
106 Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020; 11(10): 761-808 [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
107 Cho YH, Ro EJ, Yoon JS, Mizutani T, Kang DW, Park JC, Il Kim T, Clevers H, Choi KY. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation. Nat Commun 2020;11:5321. [PMID: 33087710 DOI: 10.1038/s41467-020-19173-2] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 25.3] [Reference Citation Analysis]
108 Yang Y, Han J, Ma Y, Zhang J, Zhang Z, Wang G. Demethylzeylasteral inhibits cell proliferation and enhances cell chemosensitivity to 5-fluorouracil in Colorectal Cancer cells. J Cancer 2020;11:6059-69. [PMID: 32922546 DOI: 10.7150/jca.44375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
109 Blanas A, Zaal A, van der Haar Àvila I, Kempers M, Kruijssen L, de Kok M, Popovic MA, van der Horst JC, J van Vliet S. FUT9-Driven Programming of Colon Cancer Cells towards a Stem Cell-Like State. Cancers (Basel) 2020;12:E2580. [PMID: 32927726 DOI: 10.3390/cancers12092580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
110 Abdirahman SM, Christie M, Preaudet A, Burstroem MCU, Mouradov D, Lee B, Sieber OM, Putoczki TL. A Biobank of Colorectal Cancer Patient-Derived Xenografts. Cancers (Basel) 2020;12:E2340. [PMID: 32825052 DOI: 10.3390/cancers12092340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
111 Park EJ, Baek JH, Choi GS, Park WC, Yu CS, Kang SB, Min BS, Kim JH, Kim HR, Lee BH, Oh JH, Jeong SY, Jung M, Ahn JB, Baik SH. The Role of Primary Tumor Resection in Colorectal Cancer Patients with Asymptomatic, Synchronous, Unresectable Metastasis: A Multicenter Randomized Controlled Trial. Cancers (Basel) 2020;12:E2306. [PMID: 32824392 DOI: 10.3390/cancers12082306] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
112 Beklen H, Gulfidan G, Arga KY, Mardinoglu A, Turanli B. Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer. Front Oncol. 2020;10:1273. [PMID: 32903699 DOI: 10.3389/fonc.2020.01273] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
113 Draper AS, Lafollette J, Kim C, Wu CS. Retrospective study evaluating the safety of administering pegfilgrastim on the final day of 5-fluorouracil continuous intravenous infusion. J Oncol Pharm Pract 2021;27:1159-64. [PMID: 32762293 DOI: 10.1177/1078155220945771] [Reference Citation Analysis]
114 De Lisa M, Ballatore Z, Marcantognini G, Pierantoni C, Antognoli S, Pistelli M, Pagliacci A, Berardi R. Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review. Oncol Ther 2020;8:147-60. [PMID: 32700070 DOI: 10.1007/s40487-019-00106-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
115 Miyo M, Kato T, Yoshino T, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer 2020;20:687. [PMID: 32703200 DOI: 10.1186/s12885-020-07186-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
116 Palshof JA, Cederbye CN, Høgdall EVS, Poulsen TS, Linnemann D, Nygaard SB, Stenvang J, Christensen IJ, Jensen BV, Pfeiffer P, Brünner N, Yilmaz M, Viuff BM, Nielsen DL. ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. Int J Mol Sci 2020;21:E5027. [PMID: 32708825 DOI: 10.3390/ijms21145027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
117 Kciuk M, Marciniak B, Kontek R. Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. Int J Mol Sci 2020;21:E4919. [PMID: 32664667 DOI: 10.3390/ijms21144919] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
118 Riera P, Artigas-Baleri A, Salazar J, Sebio A, Virgili AC, Arranz MJ, Páez D. ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Front Pharmacol 2020;11:973. [PMID: 32695000 DOI: 10.3389/fphar.2020.00973] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
119 Pan DC, Krishnan V, Salinas AK, Kim J, Sun T, Ravid S, Peng K, Wu D, Nurunnabi M, Nelson JA, Niziolek Z, Guo J, Mitragotri S. Hyaluronic acid-doxorubicin nanoparticles for targeted treatment of colorectal cancer. Bioeng Transl Med 2021;6:e10166. [PMID: 33532580 DOI: 10.1002/btm2.10166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
120 Zhan W, Li H, Guo Y, Du G, Wu Y, Zhang D. Construction of Biocompatible Dual-Drug Loaded Complicated Nanoparticles for in vivo Improvement of Synergistic Chemotherapy in Esophageal Cancer. Front Oncol 2020;10:622. [PMID: 32432038 DOI: 10.3389/fonc.2020.00622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
121 Sanogo S, Silimbani P, Gaggeri R, Masini C. Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin/polyamide infusion bags. J Oncol Pharm Pract 2021;27:288-96. [PMID: 32299315 DOI: 10.1177/1078155220918025] [Reference Citation Analysis]
122 Mendoza-Rodríguez MG, Sánchez-Barrera CÁ, Callejas BE, García-Castillo V, Beristain-Terrazas DL, Delgado-Buenrostro NL, Chirino YI, León-Cabrera SA, Rodríguez-Sosa M, Gutierrez-Cirlos EB, Pérez-Plasencia C, Vaca-Paniagua F, Meraz-Ríos MA, Terrazas LI. Use of STAT6 Phosphorylation Inhibitor and Trimethylglycine as New Adjuvant Therapies for 5-Fluorouracil in Colitis-Associated Tumorigenesis. Int J Mol Sci 2020;21:E2130. [PMID: 32244885 DOI: 10.3390/ijms21062130] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
123 Shi M, Ma T, Xi W, Jiang J, Wu J, Zhou C, Yang C, Zhu Z, Zhang J. A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer. Trials 2020;21:249. [PMID: 32143730 DOI: 10.1186/s13063-020-4194-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
124 Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparicio T, Hoeffel C; PRODIGE 9 Investigators and PRODIGE 20 Investigators. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut 2020;69:531-9. [PMID: 31101691 DOI: 10.1136/gutjnl-2018-316407] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 21.0] [Reference Citation Analysis]
125 Li J, Li J, Lyu N, Ma Y, Liu F, Feng Y, Yao L, Hou Z, Song X, Zhao H, Li X, Wang Y, Xiao C, Zhu B. Composition of fecal microbiota in low-set rectal cancer patients treated with FOLFOX. Ther Adv Chronic Dis 2020;11:2040622320904293. [PMID: 32153743 DOI: 10.1177/2040622320904293] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
126 Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis 2019;40:422-31. [PMID: 30590435 DOI: 10.1093/carcin/bgy186] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
127 Luput L, Sesarman A, Porfire A, Achim M, Muntean D, Casian T, Patras L, Rauca VF, Drotar DM, Stejerean I, Tomuta I, Vlase L, Dragos N, Toma VA, Licarete E, Banciu M. Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. Cancer Sci 2020;111:1344-56. [PMID: 31960547 DOI: 10.1111/cas.14312] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
128 Wang H, Huang L, Gao P, Zhu Z, Ye W, Ding H, Fang L. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. BMJ Open 2020;10:e030738. [PMID: 32051297 DOI: 10.1136/bmjopen-2019-030738] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Wong CK, Lambert AW, Ozturk S, Papageorgis P, Lopez D, Shen N, Sen Z, Abdolmaleky HM, Győrffy B, Feng H, Thiagalingam S. Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. Mol Cancer Res 2020;18:414-23. [PMID: 31932471 DOI: 10.1158/1541-7786.MCR-19-0525] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
130 Roth MT, Goff LW. Sequencing of Systemic Chemotherapy for Unresectable CRLM. Colorectal Cancer Liver Metastases 2020. [DOI: 10.1007/978-3-030-25486-5_23] [Reference Citation Analysis]
131 Mahvi DA, Mahvi DM. Liver Metastases. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00058-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
132 Karagkounis G, Choti MA. Management of Disappearing Liver Metastasis Following Preoperative Chemotherapy. Colorectal Cancer Liver Metastases 2020. [DOI: 10.1007/978-3-030-25486-5_17] [Reference Citation Analysis]
133 de Andrade CJC. Adjuvant Chemotherapy for CRLM: Indications and Results. Colorectal Cancer Liver Metastases 2020. [DOI: 10.1007/978-3-030-25486-5_19] [Reference Citation Analysis]
134 Chang CL, Yuan KS, Wu ATH, Wu SY. Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study. Cancers (Basel) 2019;11:E2003. [PMID: 31842371 DOI: 10.3390/cancers11122003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
135 Huy TL, Bui MH, Dinh TC, Xuyen HTH. Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer. Open Access Maced J Med Sci 2019;7:4244-9. [PMID: 32215071 DOI: 10.3889/oamjms.2019.368] [Reference Citation Analysis]
136 Herbrand AK, Schmitt AM, Briel M, Diem S, Ewald H, Hoogkamer A, Joerger M, Mc Cord KA, Novak U, Sricharoenchai S, Hemkens LG, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019;4:e000596. [PMID: 31803503 DOI: 10.1136/esmoopen-2019-000596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
137 Settanni CR, Quaranta G, Bibbò S, Gasbarrini A, Cammarota G, Ianiro G. Oral supplementation with lactobacilli to prevent colorectal cancer in preclinical models. Minerva Gastroenterol Dietol 2020;66:48-69. [PMID: 31760735 DOI: 10.23736/S1121-421X.19.02631-X] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
138 de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018;. [PMID: 29520731 DOI: 10.1007/s40262-018-0644-7] [Cited by in Crossref: 158] [Cited by in F6Publishing: 171] [Article Influence: 39.5] [Reference Citation Analysis]
139 Lee MKC, Loree JM. Current and emerging biomarkers in metastatic colorectal cancer. Curr Oncol 2019;26:S7-S15. [PMID: 31819705 DOI: 10.3747/co.26.5719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
140 Hashizume R, Kawahara H, Ogawa M, Suwa K, Eto K, Yanaga K. CA19-9 Concentration After First-line Chemotherapy Is Prognostic Predictor of Metastatic Colon Cancer. In Vivo 2019;33:2087-93. [PMID: 31662542 DOI: 10.21873/invivo.11708] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
141 Huang C, Huang J, Luo H, Zong Z, Zhu Z. Comparative Efficacy of Preoperative, Postoperative, and Perioperative Treatments for Resectable Colorectal Liver Metastases: A Network Meta-Analysis. Front Pharmacol 2019;10:1052. [PMID: 31619998 DOI: 10.3389/fphar.2019.01052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
142 Reita D, Bour C, Benbrika R, Groh A, Pencreach E, Guérin E, Guenot D. Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells. Cancers (Basel) 2019;11:E1581. [PMID: 31627299 DOI: 10.3390/cancers11101581] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
143 Han W, Xie B, Li Y, Shi L, Wan J, Chen X, Wang H. Orally Deliverable Nanotherapeutics for the Synergistic Treatment of Colitis-Associated Colorectal Cancer. Theranostics 2019;9:7458-73. [PMID: 31695780 DOI: 10.7150/thno.38081] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 11.5] [Reference Citation Analysis]
144 Liang Y, Hou L, Li L, Li L, Zhu L, Wang Y, Huang X, Hou Y, Zhu D, Zou H, Gu Y, Weng X, Wang Y, Li Y, Wu T, Yao M, Gross I, Gaiddon C, Luo M, Wang J, Meng X. Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene 2020;39:469-85. [PMID: 31597953 DOI: 10.1038/s41388-019-1035-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 13.5] [Reference Citation Analysis]
145 Samawi HH, Brezden-Masley C, Afzal AR, Cheung WY, Dolley A. Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada. Curr Oncol 2019;26:319-29. [PMID: 31708650 DOI: 10.3747/co.26.5107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
146 Phelip JM, Tougeron D, Léonard D, Benhaim L, Desolneux G, Dupré A, Michel P, Penna C, Tournigand C, Louvet C, Christou N, Chevallier P, Dohan A, Rousseaux B, Bouché O. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis 2019;51:1357-63. [PMID: 31320305 DOI: 10.1016/j.dld.2019.05.035] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 13.3] [Reference Citation Analysis]
147 Zhang Y, Jiang HY, Wei Y, Song B. Sinusoidal obstruction syndrome: A systematic review of etiologies, clinical symptoms, and magnetic resonance imaging features. World J Clin Cases 2019; 7(18): 2746-2759 [PMID: 31616690 DOI: 10.12998/wjcc.v7.i18.2746] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
148 Shepelytskyi Y, Fox MS, Davenport K, Li T, Albert MS, Davenport E. In-Vivo Retention of 5-Fluorouracil Using 19F Magnetic Resonance Chemical Shift Imaging in Colorectal Cancer in a Murine Model. Sci Rep 2019;9:13244. [PMID: 31519979 DOI: 10.1038/s41598-019-49716-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
149 Taneja N, Gota V, Gurjar M, Singh KK. Development and validation of high-performance liquid chromatographic method for quantification of Irinotecan and its active metabolite SN-38 in colon tumor bearing NOD/SCID mice plasma samples: application to pharmacokinetic study. Acta Chromatographica 2019;31:166-72. [DOI: 10.1556/1326.2018.00370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Galvano A, Incorvaia L, Badalamenti G, Rizzo S, Guarini A, Cusenza S, Castellana L, Barraco N, Calò V, Cutaia S, Currò G, Silvestris N, Beretta GD, Bazan V, Russo A. How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1189. [PMID: 31443300 DOI: 10.3390/cancers11081189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
151 Kim CD, Kim SH, Jung SH, Kim JH. Clinical value of an adenosine triphosphate-based chemotherapy response assay in resectable stage III colorectal cancer. Ann Surg Treat Res 2019;97:93-102. [PMID: 31384612 DOI: 10.4174/astr.2019.97.2.93] [Reference Citation Analysis]
152 Rashedi J, Ghorbani Haghjo A, Mesgari Abbasi M, Dastranj Tabrizi A, Yaqoubi S, Sanajou D, Ashrafi Jigheh Z, Namvaran A, Mohammadi A, Mohammadi Khoshraj J, Baradaran B. Anti-tumor Effect of Quercetin Loaded Chitosan Nanoparticles on Induced Colon Cancer in Wistar Rats. Adv Pharm Bull 2019;9:409-15. [PMID: 31592135 DOI: 10.15171/apb.2019.048] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
153 Herbrand A, Schmitt A, Briel M, Diem S, Ewald H, Hoogkamer A, Joerger M, Mc Cord K, Novak U, Sricharoenchai S, Hemkens L, Kasenda B. Contrasting Evidence to Reimbursement Reality for Off-label use (OLU) of Drug Treatments in Cancer Care – Rationale and Design of the CEIT-OLU-project.. [DOI: 10.1101/19003152] [Reference Citation Analysis]
154 Baek SK, Lee KT, Bae SB, Lee SC. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. Korean J Intern Med 2019;34:1188-96. [PMID: 31346151 DOI: 10.3904/kjim.2019.071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
155 Matsuhashi N, Takahashi T, Fujii H, Suetsugu T, Fukada M, Iwata Y, Tokumaru Y, Imai T, Mori R, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Futamura M, Yoshida K. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer. Mol Clin Oncol 2019;11:390-6. [PMID: 31475067 DOI: 10.3892/mco.2019.1899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
156 Jangili P, Won M, Kim SJ, Chun J, Shim I, Kang C, Ren WX, Kim JS. Binary Drug Reinforced First Small-Molecule-Based Prodrug for Synergistic Anticancer Effects. ACS Appl Bio Mater 2019;2:3532-9. [DOI: 10.1021/acsabm.9b00418] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
157 Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. JCI Insight 2019;5:127552. [PMID: 31237864 DOI: 10.1172/jci.insight.127552] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
158 Ren Y, Zhao C, He Y, Xu H, Min X. Long non-coding RNA bladder cancer-associated transcript 2 contributes to disease progression, chemoresistance and poor survival of patients with colorectal cancer. Oncol Lett 2019;18:2050-8. [PMID: 31423277 DOI: 10.3892/ol.2019.10487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
159 Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42. [PMID: 31203527 DOI: 10.1007/s10147-019-01485-z] [Cited by in Crossref: 577] [Cited by in F6Publishing: 663] [Article Influence: 144.3] [Reference Citation Analysis]
160 Legué LM, Bernards N, Lemmens VE, de Hingh IH, Creemers GJ, van Erning FN. Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice. United European Gastroenterol J 2019;7:1380-8. [PMID: 31839964 DOI: 10.1177/2050640619858211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
161 Paschke S, Hebart H, Goeb R, Staib L, Fleck U, Henne-Bruns D, Sander S, Link KH, Kornmann M. Adjuvant Chemotherapy of Locally Advanced Colon Cancer: Final Results of a Randomized Trial Comparing 5-Fluorouracil and Folinic Acid with Folfiri. Visc Med 2019;35:124-32. [PMID: 31192246 DOI: 10.1159/000491648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
162 Siveen KS, Raza A, Ahmed EI, Khan AQ, Prabhu KS, Kuttikrishnan S, Mateo JM, Zayed H, Rasul K, Azizi F, Dermime S, Steinhoff M, Uddin S. The Role of Extracellular Vesicles as Modulators of the Tumor Microenvironment, Metastasis and Drug Resistance in Colorectal Cancer. Cancers (Basel) 2019;11:E746. [PMID: 31146452 DOI: 10.3390/cancers11060746] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
163 Zhang K, Meng Y, Cao X, Xu Y, Du M, Wu Y, Liu L. Genetic variants in p53 signaling pathway genes predict chemotherapy efficacy in colorectal cancer. Cancer Med 2019;8:3428-36. [PMID: 31090204 DOI: 10.1002/cam4.2215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
164 Fernandez Montes A, Vazquez Rivera F, Martinez Lago N, Covela Rúa M, Cousillas Castiñeiras A, Gonzalez Villarroel P, de la Cámara Gómez J, Méndez Méndez JC, Salgado Fernández M, Candamio Folgar S, Reboredo López M, Carmona Campos M, Gallardo Martín E, Jorge Fernández M, Pellón Augusto ML, París Bouzas L, García Gómez J. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. Clin Transl Oncol 2020;22:351-9. [PMID: 31073972 DOI: 10.1007/s12094-019-02130-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
165 Nowak-Sliwinska P, Scapozza L, Ruiz i Altaba A. Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta Rev Cancer 2019;1871:434-54. [PMID: 31034926 DOI: 10.1016/j.bbcan.2019.04.005] [Cited by in Crossref: 90] [Cited by in F6Publishing: 71] [Article Influence: 22.5] [Reference Citation Analysis]
166 Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG)., Dutch Colorectal Cancer Group (DCCG). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer 2019;19:390. [PMID: 31023318 DOI: 10.1186/s12885-019-5545-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 63] [Article Influence: 13.3] [Reference Citation Analysis]
167 Cheung FP, Alam NZ, Wright GM. The Past, Present and Future of Pulmonary Metastasectomy: A Review Article. Ann Thorac Cardiovasc Surg 2019;25:129-41. [PMID: 30971647 DOI: 10.5761/atcs.ra.18-00229] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
168 Cinamon U, Levy D, Sokolov M, Hayat H, Roth Y. Total Laryngectomy as a Palliative Procedure for a Patient with Advanced Laryngeal and Colon Cancers: Dilemmas. J Palliat Care 2006;22:309-11. [DOI: 10.1177/082585970602200411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Toden S, Kunitoshi S, Cardenas J, Gu J, Hutchins E, Van Keuren-Jensen K, Uetake H, Toiyama Y, Goel A. Cancer stem cell-associated miRNAs serve as prognostic biomarkers in colorectal cancer. JCI Insight 2019;4:125294. [PMID: 30895943 DOI: 10.1172/jci.insight.125294] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
170 Zhou Y, Zang Y, Yang Y, Xiang J, Chen Z. Candidate genes involved in metastasis of colon cancer identified by integrated analysis. Cancer Med 2019;8:2338-47. [PMID: 30884206 DOI: 10.1002/cam4.2071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
171 Ribeiro IB, de Moura DTH, Thompson CC, de Moura EGH. Acute abdominal obstruction: Colon stent or emergency surgery? An evidence-based review. World J Gastrointest Endosc 2019; 11(3): 193-208 [PMID: 30918585 DOI: 10.4253/wjge.v11.i3.193] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
172 Emi T, Michaud K, Orton E, Santilli G, Linh C, O'Connell M, Issa F, Kennedy S. Ultrasonic Generation of Pulsatile and Sequential Therapeutic Delivery Profiles from Calcium-Crosslinked Alginate Hydrogels. Molecules 2019;24:E1048. [PMID: 30884862 DOI: 10.3390/molecules24061048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
173 Quan Q, Zhong F, Wang X, Chen K, Guo L. PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling. Oncol Res 2019;27:779-88. [PMID: 30841957 DOI: 10.3727/096504018X15442985680348] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
174 Gbolahan O, O'Neil B. Update on systemic therapy for colorectal cancer: biologics take sides. Transl Gastroenterol Hepatol 2019;4:9. [PMID: 30976712 DOI: 10.21037/tgh.2019.01.12] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
175 Jiang X, Li Q, Zhang S, Song C, Zheng P. Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer. Onco Targets Ther 2019;12:1059-70. [PMID: 30799935 DOI: 10.2147/OTT.S192290] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
176 Imanishi M, Yamamoto Y, Wang X, Sugaya A, Hirose M, Endo S, Natori Y, Yamato K, Hyodo I. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells. Cancer Sci 2019;110:639-49. [PMID: 30488540 DOI: 10.1111/cas.13893] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
177 Wang Z, Dai WP, Zang YS. Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report. Onco Targets Ther. 2019;12:443-447. [PMID: 30662270 DOI: 10.2147/ott.s180845] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
178 Kari V, Raul SK, Henck JM, Kitz J, Kramer F, Kosinsky RL, Übelmesser N, Mansour WY, Eggert J, Spitzner M, Najafova Z, Bastians H, Grade M, Gaedcke J, Wegwitz F, Johnsen SA. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness. Clin Epigenetics 2019;11:4. [PMID: 30616689 DOI: 10.1186/s13148-018-0601-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
179 Hussain M, Khera RA, Iqbal J, Khalid M, Hanif MA. Phytochemicals: Key to Effective Anticancer Drugs. MROC 2019;16:141-58. [DOI: 10.2174/1570193x15666180626113026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
180 Barreto JC, Posner MC. Management of Secondary Hepatic Neoplasms. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00134-5] [Reference Citation Analysis]
181 Larocca CJ, Jensen EH. Modern Management of Hepatic Metastatic Disease. Comprehensive Rectal Cancer Care 2019. [DOI: 10.1007/978-3-319-98902-0_24] [Reference Citation Analysis]
182 Zander T, Goede V, Hallek M. Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. Tumor Angiogenesis 2019. [DOI: 10.1007/978-3-319-33673-2_16] [Reference Citation Analysis]
183 Gao Y, Li W, Chen J, Wang X, Lv Y, Huang Y, Zhang Z, Xu F. Pharmacometabolomic prediction of individual differences of gastrointestinal toxicity complicating myelosuppression in rats induced by irinotecan. Acta Pharm Sin B 2019;9:157-66. [PMID: 30766787 DOI: 10.1016/j.apsb.2018.09.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
184 Pillai G. Nanotechnology Toward Treating Cancer. Applications of Targeted Nano Drugs and Delivery Systems 2019. [DOI: 10.1016/b978-0-12-814029-1.00009-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
185 Tan FH, Putoczki TL, Lou J, Hinde E, Hollande F, Giraud J, Stylli SS, Paradiso L, Zhu HJ, Sieber OM, Luwor RB. Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth. Cancers (Basel) 2018;10:E526. [PMID: 30572654 DOI: 10.3390/cancers10120526] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
186 Adamowicz K, Baczkowska-Waliszewska Z. Prognostic Value of Knowledge of Cancer and Used Unconventional Therapy Methods on Quality of Life in Advanced, Metastatic Colorectal Cancer in Clinical Practice. J Cancer Educ 2020;35:151-8. [PMID: 30523599 DOI: 10.1007/s13187-018-1454-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
187 Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS, Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist 2019;24:921-32. [PMID: 30552157 DOI: 10.1634/theoncologist.2018-0344] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
188 Gorbunova V, Beck JT, Hofheinz RD, Garcia-Alfonso P, Nechaeva M, Cubillo Gracian A, Mangel L, Elez Fernandez E, Deming DA, Ramanathan RK, Torres AH, Sullivan D, Luo Y, Berlin JD. A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. Br J Cancer 2019;120:183-9. [PMID: 30531832 DOI: 10.1038/s41416-018-0343-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
189 Wang D, Zhang X, Zhang Y, Wu Y, Guan X, Zhu W, Wang M, Qi C, Shen B. Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer. Onco Targets Ther 2018;11:8083-8. [PMID: 30519050 DOI: 10.2147/OTT.S180145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
190 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Nagayasu K, Sakuyama N, Sato T, Kishine K, Abe Y, Nagaoka I. Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett. 2019;17:1842-1850. [PMID: 30675246 DOI: 10.3892/ol.2017.6960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
191 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Nagayasu K, Sakuyama N, Sato T, Kishine K, Abe Y, Nagaoka I. Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett 2019;17:1842-50. [PMID: 30675246 DOI: 10.3892/ol.2018.9805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
192 Sedef AM, Taner Sümbül A. Conventıonal and targeted therapy in metastatıc colorectal cancer. JCPCR 2018;9. [DOI: 10.15406/jcpcr.2018.09.00369] [Reference Citation Analysis]
193 Adam C, Pérez-López AM, Hamilton L, Rubio-Ruiz B, Bray TL, Sieger D, Brennan PM, Unciti-Broceta A. Bioorthogonal Uncaging of the Active Metabolite of Irinotecan by Palladium-Functionalized Microdevices. Chemistry 2018;24:16783-90. [PMID: 30187973 DOI: 10.1002/chem.201803725] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
194 Chen J, Zhong J, Liu Y, Huang Y, Luo F, Zhou Y, Pan X, Cao S, Zhang L, Zhang Y, Wang J. Purified vitexin compound 1, a new neolignan isolated compound, promotes PUMA-dependent apoptosis in colorectal cancer. Cancer Med 2018;7:6158-69. [PMID: 30402948 DOI: 10.1002/cam4.1769] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
195 Ou S, Xu R, Li K, Chen Y, Kong Y, Liu H, Li J, Ouyang Y, Yu X. Radiofrequency ablation with systemic chemotherapy in the treatment of colorectal cancer liver metastasis: a 10-year single-center study. Cancer Manag Res 2018;10:5227-37. [PMID: 30464620 DOI: 10.2147/CMAR.S170160] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
196 Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. Cancer Chemother Pharmacol 2019;83:123-9. [PMID: 30377777 DOI: 10.1007/s00280-018-3711-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
197 Wang D, Chen Y, Fang H, Zheng L, Li Y, Yang F, Xu Y, Du L, Zhou BS, Li H. Increase of PRPP enhances chemosensitivity of PRPS1 mutant acute lymphoblastic leukemia cells to 5-Fluorouracil. J Cell Mol Med 2018;22:6202-12. [PMID: 30255549 DOI: 10.1111/jcmm.13907] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
198 Rocha LSDS, Riechelmann RP. Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges. Clinics (Sao Paulo) 2018;73:e542s. [PMID: 30281700 DOI: 10.6061/clinics/2018/e542s] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
199 Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 2018; 24(34): 3834-3848 [PMID: 30228778 DOI: 10.3748/wjg.v24.i34.3834] [Cited by in CrossRef: 277] [Cited by in F6Publishing: 290] [Article Influence: 55.4] [Reference Citation Analysis]
200 Sun L, Huang Y, Liu Y, Zhao Y, He X, Zhang L, Wang F, Zhang Y. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell Death Dis 2018;9:911. [PMID: 30185800 DOI: 10.1038/s41419-018-0943-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
201 Kjeldsen E, Nielsen CJF, Roy A, Tesauro C, Jakobsen AK, Stougaard M, Knudsen BR. Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL-derived Cell Line CPT-K5. Cancer Genomics Proteomics 2018;15:91-114. [PMID: 29496689 DOI: 10.21873/cgp.20068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
202 Tamagawa H, Oshima T, Aoyama T, Yoshihara K, Numata M, Sato T, Yukawa N, Mushiake H, Shiozawa M, Kunisaki C, Masuda M, Rino Y. Relationship of the tight junction protein <i>claudin-4</i> gene to outcomes in patients with colorectal cancer. Ann Cancer Res Therap 2018;26:82-88. [DOI: 10.4993/acrt.26.82] [Reference Citation Analysis]
203 Yoshino T, Oki E, Nozawa H, Eguchi-Nakajima T, Taniguchi H, Morita S, Takenaka N, Ozawa D, Shirao K. Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. ESMO Open 2018;3:e000411. [PMID: 30167332 DOI: 10.1136/esmoopen-2018-000411] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
204 Lim SW, Lee S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. J Cancer 2018;9:2910-5. [PMID: 30123359 DOI: 10.7150/jca.24948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
205 Gavriilidis P, Tobias A, Sutcliffe RP, Azoulay D, Roberts KJ. Network Meta-Analysis of Adjuvant Chemotherapy following Resection of Colorectal Liver Metastases. Gastrointest Tumors 2018;5:21-31. [PMID: 30574478 DOI: 10.1159/000490763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
206 Chen M, Liang X, Gao C, Zhao R, Zhang N, Wang S, Chen W, Zhao B, Wang J, Dai Z. Ultrasound Triggered Conversion of Porphyrin/Camptothecin-Fluoroxyuridine Triad Microbubbles into Nanoparticles Overcomes Multidrug Resistance in Colorectal Cancer. ACS Nano 2018;12:7312-26. [PMID: 29901986 DOI: 10.1021/acsnano.8b03674] [Cited by in Crossref: 84] [Cited by in F6Publishing: 90] [Article Influence: 16.8] [Reference Citation Analysis]
207 Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Fan S, Hua Y, Su W. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA 2018;319:2486-96. [PMID: 29946728 DOI: 10.1001/jama.2018.7855] [Cited by in Crossref: 95] [Cited by in F6Publishing: 107] [Article Influence: 19.0] [Reference Citation Analysis]
208 Merkel S, Schellerer VS, Wein A, Semrau S, Geppert C, Göhl J, Hohenberger W, Weber K, Grützmann R. The influence of tumour site on prognosis in metastatic colorectal carcinomas with primary tumour resection. Int J Colorectal Dis 2018;33:1215-23. [PMID: 29915904 DOI: 10.1007/s00384-018-3098-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
209 Pellino G, Gallo G, Pallante P, Capasso R, De Stefano A, Maretto I, Malapelle U, Qiu S, Nikolaou S, Barina A, Clerico G, Reginelli A, Giuliani A, Sciaudone G, Kontovounisios C, Brunese L, Trompetto M, Selvaggi F. Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterol Res Pract. 2018;2018:2397863. [PMID: 30008744 DOI: 10.1155/2018/2397863] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
210 Zhu Y, Wang G, Li X, Wang T, Weng M, Zhang Y. Knockout of SIRT4 decreases chemosensitivity to 5-FU in colorectal cancer cells. Oncol Lett 2018;16:1675-81. [PMID: 30008852 DOI: 10.3892/ol.2018.8850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
211 Cheng YM, Lin PL, Wu DW, Wang L, Huang CC, Lee H. PSMD4 is a novel therapeutic target in chemoresistant colorectal cancer activated by cytoplasmic localization of Nrf2. Oncotarget 2018;9:26342-52. [PMID: 29899863 DOI: 10.18632/oncotarget.25254] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
212 Sun J, Ren Z, Sun X, Hou H, Li K, Ge Q. Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis. Oncotarget. 2017;8:39673-39682. [PMID: 28562333 DOI: 10.18632/oncotarget.17784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
213 Rapic S, Vangestel C, Elvas F, Verhaeghe J, den Wyngaert TV, Wyffels L, Pauwels P, Staelens S, Stroobants S. Evaluation of [18F]CP18 as a Substrate-Based Apoptosis Imaging Agent for the Assessment of Early Treatment Response in Oncology. Mol Imaging Biol 2017;19:560-9. [PMID: 28050749 DOI: 10.1007/s11307-016-1037-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
214 Wang L, Chan CEL, Wong AL, Wong FC, Lim SW, Chinnathambi A, Alharbi SA, Lee LS, Soo R, Yong WP, Lee SC, Ho PC, Sethi G, Goh BC. Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1. Oncotarget 2017;8:41572-81. [PMID: 28157715 DOI: 10.18632/oncotarget.15017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
215 Landre T, Maillard E, Taleb C, Ghebriou D, Guetz GD, Zelek L, Aparicio T. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. Int J Colorectal Dis 2018;33:1125-30. [PMID: 29680896 DOI: 10.1007/s00384-018-3053-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
216 Meijerink MR, Puijk RS, van Tilborg AAJM, Henningsen KH, Fernandez LG, Neyt M, Heymans J, Frankema JS, de Jong KP, Richel DJ, Prevoo W, Vlayen J. Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. Cardiovasc Intervent Radiol. 2018;41:1189-1204. [PMID: 29666906 DOI: 10.1007/s00270-018-1959-3] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 18.8] [Reference Citation Analysis]
217 Okuno M, Goumard C, Mizuno T, Kopetz S, Omichi K, Tzeng CD, Chun YS, Lee JE, Vauthey JN, Conrad C. Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases. Br J Surg. 2018;105:1200-1209. [PMID: 29664996 DOI: 10.1002/bjs.10822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
218 Han Q, Chen R, Wang F, Chen S, Sun X, Guan X, Yang Y, Peng B, Pan X, Li J, Yi W, Li P, Zhang H, Feng D, Chen A, Li X, Li S, Yin Z. Pre-exposure to 50 Hz-electromagnetic fields enhanced the antiproliferative efficacy of 5-fluorouracil in breast cancer MCF-7 cells. PLoS One 2018;13:e0192888. [PMID: 29617363 DOI: 10.1371/journal.pone.0192888] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
219 Tie Y, Chen C, Yang Y, Qian Z, Yuan H, Wang H, Tang H, Peng Y, Du X, Liu B. Upregulation of let-7f-5p promotes chemotherapeutic resistance in colorectal cancer by directly repressing several pro-apoptotic proteins. Oncol Lett 2018;15:8695-702. [PMID: 29805607 DOI: 10.3892/ol.2018.8410] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
220 Cercek A, Gendel V, Jabbour S, Moore D, Chen C, Nosher J, Capanu M, Chou JF, Boucher T, Kemeny N, Carpizo DR. A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases. Curr Treat Options Oncol 2017;18:42. [PMID: 28608276 DOI: 10.1007/s11864-017-0481-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
221 Kim H, Baek SE, Moon J, Roh YH, Lee N, Cho A. Increased hepatic FDG uptake on PET/CT in hepatic sinusoidal obstructive syndrome. Oncotarget 2016;7:69024-31. [PMID: 27602584 DOI: 10.18632/oncotarget.11816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
222 Zhang L, Wang H, Li W, Zhong J, Yu R, Huang X, Wang H, Tan Z, Wang J, Zhang Y. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis. Oncotarget 2017;8:3289-303. [PMID: 27924057 DOI: 10.18632/oncotarget.13753] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
223 Xie T, Geng J, Wang Y, Wang L, Huang M, Chen J, Zhang K, Xue L, Liu X, Mao X, Chen Y, Wang Q, Dai T, Ren L, Yu H, Wang R, Chen L, Chen C, Chu X. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget 2017;8:8574-89. [PMID: 28051999 DOI: 10.18632/oncotarget.14351] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
224 Hu H, Wang M, Guan X, Yuan Z, Liu Z, Zou C, Wang G, Gao X, Wang X. Loss of ABCB4 attenuates the caspase-dependent apoptosis regulating resistance to 5-Fu in colorectal cancer. Biosci Rep 2018;38:BSR20171428. [PMID: 29371412 DOI: 10.1042/BSR20171428] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
225 Hernando-Cubero J, Matos-García I, Alonso-Orduña V, Capdevila J. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. J Gastrointest Cancer 2017;48:135-47. [PMID: 28397102 DOI: 10.1007/s12029-017-9946-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
226 Wang X, Sun D, Tai J, Chen S, Yu M, Ren D, Wang L. TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway. J Exp Clin Cancer Res 2018;37:27. [PMID: 29439714 DOI: 10.1186/s13046-018-0683-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 62] [Article Influence: 10.6] [Reference Citation Analysis]
227 Li AJ, Li HG, Tang EJ, Wu W, Chen Y, Jiang HH, Lin MB, Yin L. PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients. World J Gastroenterol 2018; 24(5): 631-640 [PMID: 29434452 DOI: 10.3748/wjg.v24.i5.631] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
228 O'Malley G, Heijltjes M, Houston AM, Rani S, Ritter T, Egan LJ, Ryan AE. Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response? Oncotarget 2016;7:60752-74. [PMID: 27542276 DOI: 10.18632/oncotarget.11354] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
229 Zhang S, Shi L, Mao D, Peng W, Sheng C, Ding C, Lin F, Lei C, Zhang S. Use of Jianpi Jiedu Herbs in Patients with Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2018;2018:6180810. [PMID: 29619070 DOI: 10.1155/2018/6180810] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
230 Shaojun C, Li H, Haixin H, Guisheng L. Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. Cancer Biol Ther 2018;19:153-9. [PMID: 29261002 DOI: 10.1080/15384047.2017.1414754] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
231 Silva VR, Corrêa RS, Santos LS, Soares MBP, Batista AA, Bezerra DP. A ruthenium-based 5-fluorouracil complex with enhanced cytotoxicity and apoptosis induction action in HCT116 cells. Sci Rep 2018;8:288. [PMID: 29321581 DOI: 10.1038/s41598-017-18639-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
232 Signore M, Buccarelli M, Pilozzi E, De Luca G, Cappellari M, Fanciulli M, Goeman F, Melucci E, Biffoni M, Ricci-Vitiani L. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget 2016;7:44113-28. [PMID: 27286453 DOI: 10.18632/oncotarget.9859] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
233 Stein A, Schmoll H. Which Side Effect Related to Chemotherapy Should Be Described to the Patients Before Treatment? Multidisciplinary Management of Rectal Cancer 2018. [DOI: 10.1007/978-3-319-43217-5_44] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
234 Douchy T, Lemoine L, Van der Speeten K. Early Postoperative Intraperitoneal Chemotherapy: Current Role and Future Perspectives. Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond 2018. [DOI: 10.1007/978-981-10-7053-2_5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
235 Hui JYC, Sigurdson ER. Optimizing Primary Tumor Management in Stage IV Rectal Cancer. Rectal Cancer 2018. [DOI: 10.1007/978-3-319-16384-0_16] [Reference Citation Analysis]
236 Augustin G. Intestinal Obstruction. Acute Abdomen During Pregnancy 2018. [DOI: 10.1007/978-3-319-72995-4_7] [Reference Citation Analysis]
237 Battaglin F, Puccini A, Naseem M, Schirripa M, Berger MD, Tokunaga R, McSkane M, Khoukaz T, Soni S, Zhang W, Lenz HJ. Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. J Cancer Metastasis Treat 2018;4:12. [PMID: 34532592 DOI: 10.20517/2394-4722.2018.04] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
238 Albuquerque C, Pebre Pereira L. Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment? Adv Exp Med Biol 2018;1110:75-100. [PMID: 30623367 DOI: 10.1007/978-3-030-02771-1_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
239 Lin PS, Semrad TJ. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. Methods in Molecular Biology 2018. [DOI: 10.1007/978-1-4939-7765-9_18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
240 Lee EM, Park LC, Lee HS, Shin SH, Kim YS. Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer. KMJ 2017;32:170-178. [DOI: 10.7180/kmj.2017.32.2.170] [Reference Citation Analysis]
241 Boueroy P, Hahnvajanawong C, Boonmars T, Saensa-ard S, Wattanawongdon W, Kongsanthia C, Salao K, Wongwajana S, Anantachoke N, Reutrakul V. Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma. Asian Pac J Cancer Prev 2017;18:3343-51. [PMID: 29286229 DOI: 10.22034/APJCP.2017.18.12.3343] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
242 . Colorectal Cancer. Anticancer Therapeutics 2017. [DOI: 10.1002/9781118696194.ch3.2] [Reference Citation Analysis]
243 Was H, Czarnecka J, Kominek A, Barszcz K, Bernas T, Piwocka K, Kaminska B. Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features. Cancer Biol Ther 2018;19:63-75. [PMID: 29053388 DOI: 10.1080/15384047.2017.1385675] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
244 Watanabe Y, Saito M, Saito K, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Ohki S, Takenoshita S. Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncol Lett 2018;15:2756-62. [PMID: 29435001 DOI: 10.3892/ol.2017.7650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
245 Fadlullah MZ, Chiang IK, Dionne KR, Yee PS, Gan CP, Sam KK, Tiong KH, Ng AK, Martin D, Lim KP, Kallarakkal TG, Mustafa WM, Lau SH, Abraham MT, Zain RB, Rahman ZA, Molinolo A, Patel V, Gutkind JS, Tan AC, Cheong SC. Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. Oncotarget 2016;7:27802-18. [PMID: 27050151 DOI: 10.18632/oncotarget.8533] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
246 Kikuchi D, Saito M, Saito K, Watanabe Y, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Ohki S, Takenoshita S. Upregulated solute carrier family 37 member 1 in colorectal cancer is associated with poor patient outcome and metastasis. Oncol Lett 2018;15:2065-72. [PMID: 29434906 DOI: 10.3892/ol.2017.7559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
247 Matsumoto Y, Saito M, Saito K, Kanke Y, Watanabe Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Kumamoto K, Ohki S, Takenoshita S. Enhanced expression of KIF4A in colorectal cancer is associated with lymph node metastasis. Oncol Lett 2018;15:2188-94. [PMID: 29434924 DOI: 10.3892/ol.2017.7555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
248 Toden S, Tran HM, Tovar-Camargo OA, Okugawa Y, Goel A. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget. 2016;7:16158-16171. [PMID: 26930714 DOI: 10.18632/oncotarget.7567] [Cited by in Crossref: 95] [Cited by in F6Publishing: 105] [Article Influence: 15.8] [Reference Citation Analysis]
249 Chongxi R, Hongchen W, Jiangchun L, Sheng L. Continuum of care strategy in metastatic colorectal cancer: a review. Colorectal Cancer 2017;6:95-103. [DOI: 10.2217/crc-2017-0009] [Reference Citation Analysis]
250 Noor A, Assiri A, Ayvaz S, Clark C, Dumontier M. Drug-drug interaction discovery and demystification using Semantic Web technologies. J Am Med Inform Assoc 2017;24:556-64. [PMID: 28031284 DOI: 10.1093/jamia/ocw128] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
251 Qi H, Fan W. Value of ablation therapy in the treatment of lung metastases. Thorac Cancer 2018;9:199-207. [PMID: 29193688 DOI: 10.1111/1759-7714.12567] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
252 Johnson R, Kerr D. Developing a Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction. Translational Toxicology and Therapeutics: Windows of Developmental Susceptibility in Reproduction and Cancer 2017. [DOI: 10.1002/9781119023647.ch18] [Reference Citation Analysis]
253 Russell S, Wojtkowiak J, Neilson A, Gillies RJ. Metabolic Profiling of healthy and cancerous tissues in 2D and 3D. Sci Rep 2017;7:15285. [PMID: 29127321 DOI: 10.1038/s41598-017-15325-5] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
254 Barreto R, Kitase Y, Matsumoto T, Pin F, Colston KC, Couch KE, O'Connell TM, Couch ME, Bonewald LF, Bonetto A. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci Rep 2017;7:14470. [PMID: 29089584 DOI: 10.1038/s41598-017-15040-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
255 Loupakis F, Stein A, Ychou M, Hermann F, Salud A, Österlund P. A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. Target Oncol 2016;11:293-308. [PMID: 26687849 DOI: 10.1007/s11523-015-0400-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
256 Que K, Tong Y, Que G, Li L, Lin H, Huang S, Wang R, Tang L. Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway. Oncol Rep. 2017;38:3376-3386. [PMID: 29039607 DOI: 10.3892/or.2017.6041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
257 Feoktistova PS, Karaseva VV, Khaylenko VA, Sinelnikova OA, Zharkova OV. TARGETED THERAPY IN COMPREHENSIVE MANAGEMENT OF METASTATIC COLON CANCER. Russ J Onco 2017;22:266-273. [DOI: 10.18821/1028-9984-2017-22-5-266-273] [Reference Citation Analysis]
258 Ab Mutalib NS, Md Yusof NF, Abdul SN, Jamal R. Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update. Front Pharmacol 2017;8:736. [PMID: 29075194 DOI: 10.3389/fphar.2017.00736] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
259 Aoyama T, Kashiwabara K, Oba K, Honda M, Sadahiro S, Hamada C, Maeda H, Mayanagi S, Kanda M, Sakamoto J. Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials. Cancer Med. 2017;6:2523-2530. [PMID: 28948714 DOI: 10.1002/cam4.1208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
260 Wang Y, Yi C, Wang Y, Li H, Li B, Wang D, Du J, Liu L, Wang X. Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer. Oncol Lett 2017;14:5743-52. [PMID: 29113203 DOI: 10.3892/ol.2017.6933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
261 Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D. Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Sci Rep 2017;7:10426. [PMID: 28874797 DOI: 10.1038/s41598-017-11048-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
262 Jang HJ, Kim BJ, Kim JH, Kim HS. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget. 2017;8:73009-73016. [PMID: 29069844 DOI: 10.18632/oncotarget.20314] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
263 Siesing C, Sorbye H, Dragomir A, Pfeiffer P, Qvortrup C, Pontén F, Jirström K, Glimelius B, Eberhard J. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLoS One 2017;12:e0182512. [PMID: 28800641 DOI: 10.1371/journal.pone.0182512] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
264 Tapia Rico G, Klevansky M, Townsend A, Price T. Synovial metastasis of the knee in a KRAS mutant rectal adenocarcinoma patient. BMJ Case Rep 2017;2017:bcr-2017-220008. [PMID: 28784880 DOI: 10.1136/bcr-2017-220008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
265 Ikoma N, Raghav K, Chang G. An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am. 2017;26:667-687. [PMID: 28923224 DOI: 10.1016/j.soc.2017.05.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
266 Clarke CN, Choi H, Hou P, Davis CH, Ma J, Rashid A, Vauthey JN, Aloia TA. Using MRI to non-invasively and accurately quantify preoperative hepatic steatosis. HPB (Oxford) 2017;19:706-12. [PMID: 28528267 DOI: 10.1016/j.hpb.2017.04.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
267 Cohn AL, Yoshino T, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O'Brien LM, Gao L, Yang L, Ferry D, Nasroulah F, Tabernero J. Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemother Pharmacol 2017;80:599-608. [PMID: 28744667 DOI: 10.1007/s00280-017-3380-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
268 Li P, Zhang X, Wang L, Du L, Yang Y, Liu T, Li C, Wang C. lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer. Mol Ther Nucleic Acids 2017;8:356-69. [PMID: 28918035 DOI: 10.1016/j.omtn.2017.07.007] [Cited by in Crossref: 84] [Cited by in F6Publishing: 91] [Article Influence: 14.0] [Reference Citation Analysis]
269 Zhao C, Zhao Q, Zhang C, Wang G, Yao Y, Huang X, Zhan F, Zhu Y, Shi J, Chen J, Yan F, Zhang Y. miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-κB/XIAP axis. Sci Rep 2017;7:4194. [PMID: 28646148 DOI: 10.1038/s41598-017-04172-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
270 Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 2017;317:2392-401. [PMID: 28632865 DOI: 10.1001/jama.2017.7105] [Cited by in Crossref: 460] [Cited by in F6Publishing: 506] [Article Influence: 76.7] [Reference Citation Analysis]
271 Bai Y, Wu HW, Ma X, Liu Y, Zhang YH. Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy. Onco Targets Ther 2017;10:3071-81. [PMID: 28790841 DOI: 10.2147/OTT.S137644] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
272 Xia ZS, Wu D, Zhong W, Lu XJ, Yu T, Chen QK. Wip1 gene silencing enhances the chemosensitivity of human colon cancer cells. Oncol Lett 2017;14:1875-83. [PMID: 28781635 DOI: 10.3892/ol.2017.6361] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
273 McQuade RM, Stojanovska V, Donald EL, Rahman AA, Campelj DG, Abalo R, Rybalka E, Bornstein JC, Nurgali K. Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons. Front Physiol 2017;8:391. [PMID: 28642718 DOI: 10.3389/fphys.2017.00391] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
274 Thibault V, Leguelinel-Blache G, Obled S, Loriot V, Phouttasang V, Wolf P, Bastide S, Cousin C, Favier M. [Chemotherapy for colorectal cancer: Pragmatic assessment of prescription changes and relative dose intensity]. Bull Cancer 2017;104:714-20. [PMID: 28578823 DOI: 10.1016/j.bulcan.2017.04.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
275 Tsunedomi R, Hazama S, Okayama N, Oka M, Nagano H. Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray. Cancer Sci 2017;108:1504-9. [PMID: 28474802 DOI: 10.1111/cas.13272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
276 Mehta HB, Vargas GM, Adhikari D, Dimou F, Riall TS. Comparative effectiveness of chemotherapy vs resection of the primary tumour as the initial treatment in older patients with Stage IV colorectal cancer. Colorectal Dis 2017;19:O210-8. [PMID: 28304120 DOI: 10.1111/codi.13659] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
277 Shamimi-Noori S, Gonsalves CF, Shaw CM. Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.Semin Intervent Radiol. 2017;34:145-166. [PMID: 28579683 DOI: 10.1055/s-0037-1602712] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
278 Artaç M, Coşkun HŞ, Dane F, Karabulut B, Korkmaz L, Karaağaç M, Çabuk D, Karabulut S, Faruk Aykan N, Doruk H, Avcı N, Turhal NS. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. J Gastrointest Cancer 2016;47:264-72. [PMID: 27126591 DOI: 10.1007/s12029-016-9823-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
279 He J, Pei L, Jiang H, Yang W, Chen J, Liang H. Chemoresistance of colorectal cancer to 5-fluorouracil is associated with silencing of the BNIP3 gene through aberrant methylation. J Cancer 2017;8:1187-96. [PMID: 28607593 DOI: 10.7150/jca.18171] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
280 Wang S, Wang L, Zhou Z, Deng Q, Li L, Zhang M, Liu L, Li Y. Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. Sci Rep 2017;7:682. [PMID: 28386133 DOI: 10.1038/s41598-017-00839-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
281 Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1-34. [PMID: 28349281 DOI: 10.1007/s10147-017-1101-6] [Cited by in Crossref: 492] [Cited by in F6Publishing: 539] [Article Influence: 82.0] [Reference Citation Analysis]
282 Jian YS, Chen CW, Lin CA, Yu HP, Lin HY, Liao MY, Wu SH, Lin YF, Lai PS. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo. Int J Nanomedicine 2017;12:2315-33. [PMID: 28392690 DOI: 10.2147/IJN.S120847] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
283 Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K, Murai T, Matsuda C, Oba A, Itaya K, Sone T, Yagisawa M, Koike Y, Endo A, Tsukuda Y, Ono Y, Kudo T, Nagasaka A, Nishikawa S, Komatsu Y. A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). Oncologist 2017;22:592-600. [PMID: 28341762 DOI: 10.1634/theoncologist.2016-0308] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
284 Thomas A, Bates S, Figg WD, Pommier Y. DNA Topoisomerase Targeting Drugs. Holland-Frei Cancer Medicine 2017. [DOI: 10.1002/9781119000822.hfcm060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
285 Kim MJ, Kim SJ, Park SC, Kim DY, Park JW, Ryoo SB, Jeong SY, Park KJ, Oh HK, Kim DW, Kang SB, Joo JN, Oh JH; SEoul COlorectal Group (SECOG). Adjuvant radiotherapy for the treatment of stage IV rectal cancer after curative resection: A propensity score-matched analysis and meta-analysis. Medicine (Baltimore) 2016;95:e4925. [PMID: 27893653 DOI: 10.1097/MD.0000000000004925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
286 Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget 2016;7:9309-21. [PMID: 26824184 DOI: 10.18632/oncotarget.7008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
287 Tauriello DV, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017;11:97-119. [PMID: 28085225 DOI: 10.1002/1878-0261.12018] [Cited by in Crossref: 111] [Cited by in F6Publishing: 119] [Article Influence: 18.5] [Reference Citation Analysis]
288 Grondona JP. Conversion and Neoadjuvant Therapies. Extreme Hepatic Surgery and Other Strategies 2017. [DOI: 10.1007/978-3-319-13896-1_6] [Reference Citation Analysis]
289 Sidani SM, Abbas MA. Management of the Patient with Rectal Cancer Presenting with Synchronous Liver Metastasis. Difficult Decisions in Colorectal Surgery 2017. [DOI: 10.1007/978-3-319-40223-9_20] [Reference Citation Analysis]
290 Fisher SB, Kooby DA. Systemic chemotherapy for hepatic colorectal cancer. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set 2017. [DOI: 10.1016/b978-0-323-34062-5.00100-x] [Reference Citation Analysis]
291 Brouquet A, Nordlinger B. Diagnosis and Treatment of Liver Metastases. Multidisciplinary Management of Liver Metastases in Colorectal Cancer 2017. [DOI: 10.1007/978-94-017-7755-1_2] [Reference Citation Analysis]
292 Aloia TA, Vauthey J. Hepatic metastasis from colorectal cancer. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set 2017. [DOI: 10.1016/b978-0-323-34062-5.00092-3] [Reference Citation Analysis]
293 Anandappa G. Management of Colorectal Cancer. PET/CT in Colorectal Cancer 2017. [DOI: 10.1007/978-3-319-54837-1_3] [Reference Citation Analysis]
294 Zander T, Goede V, Hallek M. Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. Tumor Angiogenesis 2017. [DOI: 10.1007/978-3-319-31215-6_16-1] [Reference Citation Analysis]
295 Chibaudel B, Tournigand C, Larsen A, de Gramont A. Chemotherapy in Patients with Initially Unresectable Liver Metastasis of Colorectal Cancer. Multidisciplinary Management of Liver Metastases in Colorectal Cancer 2017. [DOI: 10.1007/978-94-017-7755-1_16] [Reference Citation Analysis]
296 Ghiringhelli F, Richard C, Chevrier S, Végran F, Boidot R. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein. World J Gastroenterol 2016; 22(48): 10680-10686 [PMID: 28082821 DOI: 10.3748/wjg.v22.i48.10680] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
297 Kotake M, Aoyama T, Munemoto Y, Doden K, Kataoka M, Kobayashi K, Nishimura G, Fujita H, Nakamura K, Takehara A, Tanaka C, Sakamoto J, Nagata N, Oba K, Kondo K. Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial). Oncol Lett 2017;13:747-53. [PMID: 28356954 DOI: 10.3892/ol.2016.5505] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
298 Kumar S, Noel MS, Khorana AA. Advances in adjuvant therapy of colon cancer. Seminars in Colon and Rectal Surgery 2016;27:204-212. [DOI: 10.1053/j.scrs.2016.04.019] [Reference Citation Analysis]
299 Razenberg LG, Creemers GJ, Beerepoot LV, Vos AH, van de Wouw AJ, Maas HA, Lemmens VE. Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer. Acta Oncol 2016;55:1443-9. [PMID: 27585122 DOI: 10.1080/0284186X.2016.1223880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
300 Douillard J. Irinotecan: a new treatment in metastatic colorectal cancer. J Oncol Pharm Pract 2000;6:S3-9. [DOI: 10.1177/107815520000600i301] [Reference Citation Analysis]
301 Chiang NJ, Chao TY, Hsieh RK, Wang CH, Wang YW, Yeh CG, Chen LT. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. BMC Cancer 2016;16:907. [PMID: 27871319 DOI: 10.1186/s12885-016-2933-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
302 Kim HY, Kim J, Ha Thi HT, Bang OS, Lee WS, Hong S. Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model. BMC Complement Altern Med 2016;16:473. [PMID: 27863496 DOI: 10.1186/s12906-016-1447-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
303 Riechelmann R, Grothey A. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol 2017;9:106-26. [PMID: 28203302 DOI: 10.1177/1758834016676703] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
304 El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther 2015;16:1726-37. [PMID: 26553611 DOI: 10.1080/15384047.2015.1113356] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 8.1] [Reference Citation Analysis]
305 Avan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol 2016; 7(5): 352-369 [PMID: 27777878 DOI: 10.5306/wjco.v7.i5.352] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
306 Suzuki S, Shimazaki J, Morishita K, Koike N, Harada N, Hayashi T, Suzuki M. Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer. Mol Clin Oncol 2016;5:391-4. [PMID: 27699032 DOI: 10.3892/mco.2016.977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
307 Zhang Y, Liu Y, Ye Y, Shen D, Zhang H, Huang H, Li S, Wang S, Ren J. Quantitative proteome analysis of colorectal cancer-related differential proteins. J Cancer Res Clin Oncol 2017;143:233-41. [PMID: 27659785 DOI: 10.1007/s00432-016-2274-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
308 Guo JR, Chen QQ, Lam CW, Wang CY, Xu FG, Liu BM, Zhang W. Effect of Phyllanthus amarus Extract on 5-Fluorouracil-Induced Perturbations in Ribonucleotide and Deoxyribonucleotide Pools in HepG2 Cell Line. Molecules 2016;21:E1254. [PMID: 27657029 DOI: 10.3390/molecules21091254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
309 Aung KL, Stockley TL, Serra S, Kamel-Reid S, Bedard PL, Siu LL. Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Cold Spring Harb Mol Case Stud 2016;2:a001016. [PMID: 27626067 DOI: 10.1101/mcs.a001016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
310 Lu D, Song H, He F, Cui B, Li Y, Wu T; Cochrane Colorectal Cancer Group. Chemotherapy with Camptothecin compounds for metastatic colorectal cancer. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd007521.pub2] [Reference Citation Analysis]
311 Summerhayes M. Capecitabine: a novel, orally administered, tumour-activated treatment for colorectal cancer. J Oncol Pharm Pract 2001;7:107-25. [DOI: 10.1191/1078155201jp085oa] [Reference Citation Analysis]
312 McNair AG, Macefield RC, Blencowe NS, Brookes ST, Blazeby JM. 'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic Review. PLoS One 2016;11:e0160998. [PMID: 27571514 DOI: 10.1371/journal.pone.0160998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
313 Botrel TEA, Clark LGO, Paladini L, Clark OAC. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16:677. [PMID: 27558497 DOI: 10.1186/s12885-016-2734-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 66] [Article Influence: 8.0] [Reference Citation Analysis]
314 Cisterna BA, Kamaly N, Choi WI, Tavakkoli A, Farokhzad OC, Vilos C. Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) 2016;11:2443-56. [PMID: 27529192 DOI: 10.2217/nnm-2016-0194] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 12.7] [Reference Citation Analysis]
315 Xu W, Kuang M, Gong Y, Cao C, Chen J, Tang C. Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis. Onco Targets Ther 2016;9:4833-42. [PMID: 27536147 DOI: 10.2147/OTT.S104981] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
316 Facciorusso A, Del Prete V, Muscatiello N, Crucinio N, Barone M. Prognostic role of 25-hydroxyvitamin D in patients with liver metastases from colorectal cancer treated with radiofrequency ablation. J Gastroenterol Hepatol 2016;31:1483-8. [PMID: 26896637 DOI: 10.1111/jgh.13326] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
317 Uemura M, Kim HM, Hata T, Sakata K, Okuyama M, Takemoto H, Fujii H, Fukuzaki T, Morita T, Hata T, Takemasa I, Satoh T, Mizushima T, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer. Mol Clin Oncol 2016;5:375-9. [PMID: 27446583 DOI: 10.3892/mco.2016.938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
318 Vijayvergia N, Li T, Wong YN, Hall MJ, Cohen SJ, Dotan E. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. Cancer 2016;122:3191-8. [PMID: 27379436 DOI: 10.1002/cncr.30077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
319 Bretschneider T, Ricke J, Gebauer B, Streitparth F. Image-guided high-dose-rate brachytherapy of malignancies in various inner organs - technique, indications, and perspectives. J Contemp Brachytherapy 2016;8:251-61. [PMID: 27504135 DOI: 10.5114/jcb.2016.61068] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
320 Bupathi M, Ahn DH, Bekaii-Saab T. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer 2016;6:21-30. [PMID: 28190957 DOI: 10.2147/GICTT.S97740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
321 Nietzer S, Baur F, Sieber S, Hansmann J, Schwarz T, Stoffer C, Häfner H, Gasser M, Waaga-Gasser AM, Walles H, Dandekar G. Mimicking Metastases Including Tumor Stroma: A New Technique to Generate a Three-Dimensional Colorectal Cancer Model Based on a Biological Decellularized Intestinal Scaffold. Tissue Eng Part C Methods 2016;22:621-35. [PMID: 27137941 DOI: 10.1089/ten.TEC.2015.0557] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
322 Huynh N, Shulkes A, Baldwin G, He H. Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer. Cancer Biol Ther 2016;17:813-23. [PMID: 27260988 DOI: 10.1080/15384047.2016.1195045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
323 Buhl IK, Gerster S, Delorenzi M, Jensen T, Jensen PB, Bosman F, Tejpar S, Roth A, Brunner N, Hansen A, Knudsen S. Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data. PLoS One 2016;11:e0155123. [PMID: 27171152 DOI: 10.1371/journal.pone.0155123] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
324 McCulloch M, Ly H, Broffman M, See C, Clemons J, Chang R. Chinese Herbal Medicine and Fluorouracil-Based Chemotherapy for Colorectal Cancer: A Quality-Adjusted Meta-Analysis of Randomized Controlled Trials. Integr Cancer Ther 2016;15:285-307. [PMID: 27151587 DOI: 10.1177/1534735416638738] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
325 Facciorusso A, Del Prete V, Crucinio N, Serviddio G, Vendemiale G, Muscatiello N. Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases. World J Gastroenterol 2016; 22(16): 4211-4218 [PMID: 27122671 DOI: 10.3748/wjg.v22.i16.4211] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
326 Osuga T, Takimoto R, Ono M, Hirakawa M, Yoshida M, Okagawa Y, Uemura N, Arihara Y, Sato Y, Tamura F, Sato T, Iyama S, Miyanishi K, Takada K, Hayashi T, Kobune M, Kato J. Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer. J Natl Cancer Inst 2016;108. [PMID: 27075853 DOI: 10.1093/jnci/djw038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
327 Semrad TJ, Kim EJ. Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. J Gastrointest Oncol. 2016;7:S11-S20. [PMID: 27034809 DOI: 10.3978/j.issn.2078-6891.2015.094] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
328 Shimura T, Joh T. Evidence-based Clinical Management of Acute Malignant Colorectal Obstruction. J Clin Gastroenterol 2016;50:273-85. [PMID: 26796083 DOI: 10.1097/MCG.0000000000000475] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
329 Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016;9:1899-920. [PMID: 27099521 DOI: 10.2147/OTT.S95101] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
330 Sag AA, Selcukbiricik F, Mandel NM. Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol 2016; 22(11): 3127-3149 [PMID: 27003990 DOI: 10.3748/wjg.v22.i11.3127] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
331 Nassour I, Polanco PM. Minimally Invasive Liver Surgery for Hepatic Colorectal Metastases. Curr Colorectal Cancer Rep 2016;12:103-12. [PMID: 27570500 DOI: 10.1007/s11888-016-0316-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
332 Hu Y, Yu W, Song L, Du XH, Ma X, Liu Y, Wu J, Ying Y. Effects of light on production of camptothecin and expression of key enzyme genes in seedlings of Camptotheca acuminate Decne. Acta Physiol Plant 2016;38. [DOI: 10.1007/s11738-016-2084-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
333 Tarpgaard LS, Qvortrup C, Nygård SB, Nielsen SL, Andersen DR, Jensen NF, Stenvang J, Detlefsen S, Brünner N, Pfeiffer P. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. BMC Cancer 2016;16:91. [PMID: 26867764 DOI: 10.1186/s12885-016-2124-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
334 Le Roy B, Tixier L, Pereira B, Sauvanet P, Buc E, Pétorin C, Déchelotte P, Pezet D, Balayssac D. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study. PLoS One 2016;11:e0148739. [PMID: 26859833 DOI: 10.1371/journal.pone.0148739] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
335 Yi L, Lin G, Zhang K, Wang L, Zhang R, Xie J, Li J. Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China. PLoS One 2016;11:e0148081. [PMID: 26820647 DOI: 10.1371/journal.pone.0148081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
336 Yeh YS, Tsai HL, Huang CW, Wang JH, Lin YW, Tang HC, Sung YC, Wu CC, Lu CY, Wang JY. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial. Trials 2016;17:46. [PMID: 26811156 DOI: 10.1186/s13063-016-1153-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
337 Lungoci C, Mironiuc AI, Muntean V, Oniu T, Leebmann H, Mayr M, Piso P. Multimodality treatment strategies have changed prognosis of peritoneal metastases. World J Gastrointest Oncol 2016; 8(1): 67-82 [PMID: 26798438 DOI: 10.4251/wjgo.v8.i1.67] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
338 Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall’Olio FG, Barbera MA, Pantaleo MA, Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol 2016; 22(2): 519-533 [PMID: 26811604 DOI: 10.3748/wjg.v22.i2.519] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
339 Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57-84. [PMID: 26753006 DOI: 10.1177/1758834015614530] [Cited by in Crossref: 263] [Cited by in F6Publishing: 287] [Article Influence: 37.6] [Reference Citation Analysis]
340 Malik L, Weitman S. Overview of Oncology Drug Development. Pharmacokinetics in Drug Development 2016. [DOI: 10.1007/978-3-319-39053-6_1] [Reference Citation Analysis]
341 Wang L, Wang Y, Lu Y, Zhang Q, Qu X. Heterozygous deletion of ATG5 in Apc(Min/+) mice promotes intestinal adenoma growth and enhances the antitumor efficacy of interferon-gamma. Cancer Biol Ther. 2015;16:383-391. [PMID: 25695667 DOI: 10.1080/15384047.2014.1002331] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
342 Nakayama M, Yoshimatsu K, Yokomizo H, Yano Y, Okayama S, Naritaka Y. A Case of KRAS Exon 2 Wild Colorectal Cancer Resistant to the Anti-EGFR Therapy. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2016;77:2259-2263. [DOI: 10.3919/jjsa.77.2259] [Reference Citation Analysis]
343 Miyata Y, Touyama T, Kusumi T, Morita Y, Mizunuma N, Taniguchi F, Manabe M. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. Int J Clin Oncol. 2016;21:696-703. [PMID: 26710796 DOI: 10.1007/s10147-015-0937-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
344 Aranda E, Aparicio J, Alonso V, Garcia-Albeniz X, Garcia-Alfonso P, Salazar R, Valladares M, Vera R, Vieitez JM, Garcia-Carbonero R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clin Transl Oncol 2015;17:972-81. [PMID: 26669312 DOI: 10.1007/s12094-015-1434-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
345 Sethi MK, Fanayan S. Mass Spectrometry-Based N-Glycomics of Colorectal Cancer. Int J Mol Sci 2015;16:29278-304. [PMID: 26690136 DOI: 10.3390/ijms161226165] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
346 Xiao XG, Xia S, Zou M, Mei Q, Zhou L, Wang SJ, Chen Y. The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. Onco Targets Ther 2015;8:3575-83. [PMID: 26664141 DOI: 10.2147/OTT.S95149] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
347 Luther J, Chan AT. Malignant Tumors of the Colon. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch78] [Reference Citation Analysis]
348 Fujita KI, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 2015; 21(43): 12234-12248 [PMID: 26604633 DOI: 10.3748/wjg.v21.i43.12234] [Cited by in CrossRef: 164] [Cited by in F6Publishing: 168] [Article Influence: 20.5] [Reference Citation Analysis]
349 Guo J, Chen Q, Lam CW, Wang C, Wong VK, Xu F, Jiang Z, Zhang W. Application of artificial neural network to investigate the effects of 5-fluorouracil on ribonucleotides and deoxyribonucleotides in HepG2 cells. Sci Rep 2015;5:16861. [PMID: 26578061 DOI: 10.1038/srep16861] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
350 Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H, Ishioka C. DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Sci 2015;106:1722-9. [PMID: 26426205 DOI: 10.1111/cas.12827] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
351 Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, Gajjar A. Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro Oncol 2015;17:1620-7. [PMID: 26541630 DOI: 10.1093/neuonc/nov181] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
352 Stintzing S, Heinemann V. Wahl der Behandlungsstrategie auf der Basis molekularer Marker. Im Focus Onkologie 2015;18:51-59. [DOI: 10.1007/s15015-015-1827-9] [Reference Citation Analysis]
353 Pereira AA, Rego JF, Munhoz RR, Hoff PM, Sasse AD, Riechelmann RP. The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials. Acta Oncol 2015;54:1737-46. [PMID: 25984931 DOI: 10.3109/0284186X.2015.1044022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
354 Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall T, Mohan NK, Eldon MA, Hoch U, Lockman PR. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC Cancer 2015;15:685. [PMID: 26463521 DOI: 10.1186/s12885-015-1672-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
355 Santini FC, Braghiroli MI, Hoff PM. Are There Strategies to Integrate the Continuum of Care for Metastatic Colorectal Cancer When Resources Are Limited? Curr Colorectal Cancer Rep 2015;11:311-6. [DOI: 10.1007/s11888-015-0294-1] [Reference Citation Analysis]
356 Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Yamazoe S, Kimura K, Toyokawa T, Amano R, Tanaka H, Muguruma K, Hirakawa K. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. World J Gastroenterol 2015; 21(34): 9966-9973 [PMID: 26379401 DOI: 10.3748/wjg.v21.i34.9966] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 60] [Article Influence: 6.8] [Reference Citation Analysis]
357 Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol 2015;76:925-32. [PMID: 26370544 DOI: 10.1007/s00280-015-2850-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
358 Wallace BD, Roberts AB, Pollet RM, Ingle JD, Biernat KA, Pellock SJ, Venkatesh MK, Guthrie L, O'Neal SK, Robinson SJ, Dollinger M, Figueroa E, McShane SR, Cohen RD, Jin J, Frye SV, Zamboni WC, Pepe-Ranney C, Mani S, Kelly L, Redinbo MR. Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity. Chem Biol 2015;22:1238-49. [PMID: 26364932 DOI: 10.1016/j.chembiol.2015.08.005] [Cited by in Crossref: 154] [Cited by in F6Publishing: 164] [Article Influence: 19.3] [Reference Citation Analysis]
359 Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol 2015;7:252-62. [PMID: 26327923 DOI: 10.1177/1758834015591952] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 6.0] [Reference Citation Analysis]
360 Kim JH, Zang DY, Chung IJ, Cho SH, Park KU, Oh HS, Lee KH, Lee BH, Kim MJ, Park CK, Han B, Kim HS, Choi DR, Song HH, Jung JY. A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer. J Cancer. 2015;6:1041-1048. [PMID: 26366218 DOI: 10.7150/jca.12819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
361 Teng CL, Wang CY, Chen YH, Lin CH, Hwang WL. Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study. PLoS One 2015;10:e0135673. [PMID: 26273837 DOI: 10.1371/journal.pone.0135673] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
362 Ogata Y, Ishibashi N, Yamaguchi K, Uchida S, Kamei H, Nakayama G, Hirakawa H, Tanigawa M, Akagi Y. Preventive effects of amino-acid-rich elemental diet Elental® on chemotherapy-induced oral mucositis in patients with colorectal cancer: a prospective pilot study. Support Care Cancer 2016;24:783-9. [PMID: 26266658 DOI: 10.1007/s00520-015-2844-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
363 Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol 2015;12:607-19. [PMID: 26215044 DOI: 10.1038/nrclinonc.2015.129] [Cited by in Crossref: 109] [Cited by in F6Publishing: 114] [Article Influence: 13.6] [Reference Citation Analysis]
364 Kim AY, Kwak JH, Je NK, Lee YH, Jung YS. Epithelial-mesenchymal Transition is Associated with Acquired Resistance to 5-Fluorocuracil in HT-29 Colon Cancer Cells. Toxicol Res 2015;31:151-6. [PMID: 26191381 DOI: 10.5487/TR.2015.31.2.151] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
365 Linton SS, Sherwood SG, Drews KC, Kester M. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016;8:208-22. [PMID: 26153136 DOI: 10.1002/wnan.1358] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
366 Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer. 2015;15:496. [PMID: 26141683 DOI: 10.1186/s12885-015-1503-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
367 Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach. J Hepatol 2015;63:102-13. [PMID: 25660209 DOI: 10.1016/j.jhep.2015.01.031] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 6.5] [Reference Citation Analysis]
368 Mayrbäurl B, Giesinger JM, Burgstaller S, Piringer G, Holzner B, Thaler J. Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study. Support Care Cancer 2016;24:667-74. [PMID: 26123602 DOI: 10.1007/s00520-015-2828-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
369 Wood JP, Smith AJ, Bowman KJ, Thomas AL, Jones GD. Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo. Cancer Med 2015;4:1309-21. [PMID: 26108357 DOI: 10.1002/cam4.477] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
370 Ishida K, Uesugi N, Hasegawa Y, Sugimoto R, Takahara T, Otsuka K, Nitta H, Kawasaki T, Wakabayashi G, Sugai T. Proposal for novel histological findings of colorectal liver metastases with preoperative chemotherapy. Pathol Int 2015;65:367-73. [PMID: 25940915 DOI: 10.1111/pin.12300] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
371 Shibutani M, Maeda K, Nagahara H, Ohtani H, Iseki Y, Ikeya T, Sugano K, Hirakawa K. The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. BMC Cancer 2015;15:347. [PMID: 25934494 DOI: 10.1186/s12885-015-1375-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
372 Homayounfar K, Mey D, Boos M, Gaedcke J, Ghadimi M. Kommunikation im Tumorboard. Forum 2015;30:214-217. [DOI: 10.1007/s12312-015-1301-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
373 Liu Y, DU F, Zhao Q, Jin J, Ma X, Li H. Acquisition of 5-fluorouracil resistance induces epithelial-mesenchymal transitions through the Hedgehog signaling pathway in HCT-8 colon cancer cells. Oncol Lett 2015;9:2675-9. [PMID: 26137127 DOI: 10.3892/ol.2015.3136] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
374 Zhu GQ, You J, Shi KQ, He SY, Wang LR, Chen YP, Braddock M, Zheng MH. Systematic review with network meta-analysis: adjuvant chemotherapy for resected colorectal liver metastases. Medicine (Baltimore) 2015;94:e379. [PMID: 25569666 DOI: 10.1097/MD.0000000000000379] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
375 Murad AM, Murad LS. First-Line Therapy in Metastatic Colorectal Cancer Patients Not Candidates for Curative Surgery. Curr Colorectal Cancer Rep 2015;11:54-69. [DOI: 10.1007/s11888-015-0259-4] [Reference Citation Analysis]
376 Aguilar G, Albiol S, Alcaide J, Alonso M, Alonso V, Andreu M, Aparicio J, de la Vega FA, Arrivi A, Ayuso JR, Bohn U, Bouzas R, Cano JM, Castañón C, Castells A, Cerdà P, Cerezo L, Conill C, Cuatrecasas M, Pozo MND, Delgado JI, Enriquez-navascues JM, Escudero P, Espín E, l RE, Falcó E, Farré J, Feliu J, Fernández-martos C, Ferrer AI, Gallego R, Galvez E, de Albéniz XG, Olmo DG, García-carbonero R, Dorronsoro MG, Martín CG, Moreno SG, Hernández A, Iraola A, Jímenez E, Jiménez MC, Jurado I, Leno R, León A, Martín E, Martín M, Maurel J, Méndez JC, Méndez R, Palma P, Pardo F, Pereira F, Pérez-altozano J, Pérez E, Rodríguez J, Ruiz-casado AI, Sabater L, Sarría L, Segura A, Sevilla I, Tobeña M, Torres E, Viudez A, Zanui M, Zorrilla M. Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Español Multidisciplinar en Cancer Digestivo (GEMCAD). Colorectal Cancer 2015;4:97-112. [DOI: 10.2217/crc.15.9] [Reference Citation Analysis]
377 Aparicio T, Linot B, Le Malicot K, Bouché O, Boige V, François E, Ghiringhelli F, Legoux JL, Ben Abdelghani M, Phelip JM, Faroux R, Dahan L, Taieb J, Bedenne L. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802). Dig Liver Dis 2015;47:271-2. [PMID: 25677925 DOI: 10.1016/j.dld.2015.01.146] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
378 Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015;6:185-200. [PMID: 25830038 DOI: 10.3978/j.issn.2078-6891.2014.112] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
379 Galli L, Ricci C, Egan CG. Epoetin beta for the treatment of chemotherapy-induced anemia: an update. Onco Targets Ther 2015;8:583-91. [PMID: 25784818 DOI: 10.2147/OTT.S77497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
380 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207-239. [PMID: 25782566 DOI: 10.1007/s10147-015-0801-z] [Cited by in Crossref: 422] [Cited by in F6Publishing: 412] [Article Influence: 52.8] [Reference Citation Analysis]
381 Paré-Brunet L, Sebio A, Salazar J, Berenguer-Llergo A, Río E, Barnadas A, Baiget M, Páez D. Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. Pharmacogenomics J 2015;15:397-404. [PMID: 25707392 DOI: 10.1038/tpj.2015.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
382 Serafino A, Moroni N, Zonfrillo M, Andreola F, Mercuri L, Nicotera G, Nunziata J, Ricci R, Antinori A, Rasi G, Pierimarchi P. WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer. Oncotarget 2014;5:978-92. [DOI: 10.18632/oncotarget.1571] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
383 Sawano T, Shimizu T, Yamada T, Nanashima N, Miura T, Morohashi S, Kudo D, Hui FM, Kijima H, Hakamada K, Tsuchida S. Fatty acid synthase-positive hepatocytes and subsequent steatosis in rat livers by irinotecan. Oncol Rep 2015;33:2151-60. [PMID: 25708528 DOI: 10.3892/or.2015.3814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
384 Kassahun WT. Unresolved issues and controversies surrounding the management of colorectal cancer liver metastasis. World J Surg Oncol 2015;13:61. [PMID: 25890279 DOI: 10.1186/s12957-014-0420-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
385 Hsu TC. TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer. Oncol Lett 2015;9:1059-64. [PMID: 25663857 DOI: 10.3892/ol.2015.2855] [Reference Citation Analysis]
386 Toden S, Okugawa Y, Jascur T, Wodarz D, Komarova NL, Buhrmann C, Shakibaei M, Boland CR, Goel A. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis 2015;36:355-67. [PMID: 25653233 DOI: 10.1093/carcin/bgv006] [Cited by in Crossref: 146] [Cited by in F6Publishing: 162] [Article Influence: 18.3] [Reference Citation Analysis]
387 Yamamoto T, Uemura K, Moriyama K, Mitamura K, Taga A. Inhibitory effect of maple syrup on the cell growth and invasion of human colorectal cancer cells. Oncol Rep 2015;33:1579-84. [PMID: 25647359 DOI: 10.3892/or.2015.3777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
388 Aparicio T. Quoi de neuf pour l’adénocarcinome colorectal depuis la fin du dernier millénaire ? Colon Rectum 2015;9:19-24. [DOI: 10.1007/s11725-015-0562-x] [Reference Citation Analysis]
389 Nordlinger B, Jaeck D. Le traitement multidisciplinaire. Bulletin de l'Académie Nationale de Médecine 2015;199:213-222. [DOI: 10.1016/s0001-4079(19)30964-1] [Reference Citation Analysis]
390 Jones RG, Tan D. How can we determine the best neoadjuvant chemoradiotherapy regimen for rectal cancer? Colorectal Cancer 2015;4:37-52. [DOI: 10.2217/crc.15.3] [Reference Citation Analysis]
391 Lee YJ, Kim JH, Kim SW, Kang WC, Kim SJ, Kim JH, Kim SJ. A Case of Organizing Pneumonia Associated with FOLFIRI Chemotherapy. Tuberc Respir Dis (Seoul) 2014;77:262-5. [PMID: 25580143 DOI: 10.4046/trd.2014.77.6.262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
392 Maeda H, Hazama S, Shavkat A, Okamoto K, Oba K, Sakamoto J, Takahashi K, Oka M, Nakamura D, Tsunedomi R, Okayama N, Mishima H, Kobayashi M. Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations. Mol Diagn Ther 2014;18:333-42. [PMID: 24453052 DOI: 10.1007/s40291-014-0083-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
393 Pesenti C, Gusella M, Sirchia SM, Miozzo M. Germline oncopharmacogenetics, a promising field in cancer therapy. Cell Oncol (Dordr) 2015;38:65-89. [PMID: 25573079 DOI: 10.1007/s13402-014-0214-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
394 Kørner H, Søreide JA. Surgical Treatment in Palliative Care. Multidisciplinary Treatment of Colorectal Cancer 2015. [DOI: 10.1007/978-3-319-06142-9_25] [Reference Citation Analysis]
395 E28 Literaturhinweise und Internetadressen. Facharzt Hämatologie Onkologie 2015. [DOI: 10.1016/b978-3-437-21213-0.16001-2] [Reference Citation Analysis]
396 Pfeiffer P, Qvortrup C, Tabernero J. Systemic Therapy for Patients with Colorectal Cancer: State of the Art. Multidisciplinary Treatment of Colorectal Cancer 2015. [DOI: 10.1007/978-3-319-06142-9_13] [Reference Citation Analysis]
397 Canbay E, Yonemura Y. Management of Special Issues. Peritoneal Surface Malignancies 2015. [DOI: 10.1007/978-3-319-12937-2_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
398 Halfdanarson TR, Hubbard JM. Metastatic Rectal Cancer. Modern Management of Cancer of the Rectum 2015. [DOI: 10.1007/978-1-4471-6609-2_20] [Reference Citation Analysis]
399 Ding HH, Wu WD, Jiang T, Cao J, Ji ZY, Jin JH, Wang JJ, Song WF, Wang LW. Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). Tumour Biol 2015;36:3361-9. [PMID: 25534239 DOI: 10.1007/s13277-014-2970-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
400 Li W, Xu J, Shen L, Liu T, Guo W, Zhang W, Chen Z, Zhu X, Li J. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. BMC Cancer 2014;14:986. [PMID: 25527007 DOI: 10.1186/1471-2407-14-986] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
401 Meisenberg C, Gilbert DC, Chalmers A, Haley V, Gollins S, Ward SE, El-Khamisy SF. Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan. Mol Cancer Ther. 2015;14:575-585. [PMID: 25522766 DOI: 10.1158/1535-7163.mct-14-0762] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
402 Asmis T, Berry S, Cosby R, Chan K, Coburn N, Rother M. Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. Curr Oncol. 2014;21:318-328. [PMID: 25489259 DOI: 10.3747/co.21.2146] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
403 Tohme S, Sukato D, Nace GW, Zajko A, Amesur N, Orons P, Chalhoub D, Marsh JW, Geller DA, Tsung A. Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer. HPB (Oxford) 2014;16:1110-6. [PMID: 25123597 DOI: 10.1111/hpb.12307] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
404 Katalinic D, Santek F, Juretic A, Skegro D, Plestina S. Gastroenteropancreatic neuroendocrine tumour arising in Meckel's diverticulum coexisting with colon adenocarcinoma. World J Surg Oncol 2014;12:358. [PMID: 25427657 DOI: 10.1186/1477-7819-12-358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
405 Fernandez-Plana J, Pericay C, Quintero G, Alonso V, Salud A, Mendez M, Salgado M, Saigi E, Cirera L; ACROSS Study Group. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). BMC Cancer 2014;14:865. [PMID: 25417182 DOI: 10.1186/1471-2407-14-865] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
406 Horiguchi H, Endo M, Miyamoto Y, Sakamoto Y, Odagiri H, Masuda T, Kadomatsu T, Tanoue H, Motokawa I, Terada K, Morioka MS, Manabe I, Baba H, Oike Y. Angiopoietin-like protein 2 renders colorectal cancer cells resistant to chemotherapy by activating spleen tyrosine kinase-phosphoinositide 3-kinase-dependent anti-apoptotic signaling. Cancer Sci 2014;105:1550-9. [PMID: 25287946 DOI: 10.1111/cas.12554] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
407 Stintzing S. Management of colorectal cancer. F1000Prime Rep 2014;6:108. [PMID: 25580262 DOI: 10.12703/P6-108] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 6.8] [Reference Citation Analysis]
408 Glockzin G, Gerken M, Lang SA, Klinkhammer-Schalke M, Piso P, Schlitt HJ. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis. BMC Cancer. 2014;14:807. [PMID: 25369730 DOI: 10.1186/1471-2407-14-807] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
409 Yang S, Alibhai SM, Kennedy ED, El-Sedfy A, Dixon M, Coburn N, Kiss A, Law CH. Optimal management of colorectal liver metastases in older patients: a decision analysis. HPB (Oxford) 2014;16:1031-42. [PMID: 24961482 DOI: 10.1111/hpb.12292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
410 Hirashima T, Nagai T, Shigeoka H, Tamura Y, Yoshida H, Kawahara K, Kondoh Y, Sakai K, Hashimoto S, Fujishima M, Shiroyama T, Tamiya M, Morishita N, Suzuki H, Okamoto N, Kawase I. Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study. BMC Cancer 2014;14:770. [PMID: 25326267 DOI: 10.1186/1471-2407-14-770] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
411 Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther. 2014;7:1817-1828. [PMID: 25336973 DOI: 10.2147/OTT.S48409ott-7-1817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
412 Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther. 2014;7:1817-1828. [PMID: 25336973 DOI: 10.2147/OTT.S48409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 23] [Article Influence: 0.3] [Reference Citation Analysis]
413 Jouinot A, Coriat R, Huillard O, Goldwasser F. Les biothérapies des cancers colorectaux métastatiques en 2014. La Presse Médicale 2014;43:1056-66. [DOI: 10.1016/j.lpm.2014.03.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
414 Rosati G, Aprile G, Poletto E, Avallone A. An update on the management of metastatic colorectal cancer in the elderly. Colorectal Cancer 2014;3:451-463. [DOI: 10.2217/crc.14.32] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
415 Bennouna J, Deslandres M, Senellart H, de Labareyre C, Ruiz-Soto R, Wixon C, Botbyl J, Suttle AB, Delord JP. A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Invest New Drugs 2015;33:138-47. [PMID: 25248752 DOI: 10.1007/s10637-014-0142-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
416 Li M, Wang Z, Guo J, Liu J, Li C, Liu L, Shi H, Liu L, Li H, Xie C, Zhang X, Sun W, Fang S, Bi X. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther 2014;7:1653-61. [PMID: 25285015 DOI: 10.2147/OTT.S67867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 19] [Article Influence: 0.2] [Reference Citation Analysis]
417 Hoch U, Staschen CM, Johnson RK, Eldon MA. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol 2014;74:1125-37. [PMID: 25228368 DOI: 10.1007/s00280-014-2577-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
418 Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor MD, Chaves M. MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer. 2014;14:656. [PMID: 25197016 DOI: 10.1186/1471-2407-14-656] [Cited by in Crossref: 48] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
419 Garrido-castro AC, Sauri-nadal T, Macarulla-mercadé T. New Targets and New Drug Development in Colorectal Cancer. Curr Colorectal Cancer Rep 2014;10:288-295. [DOI: 10.1007/s11888-014-0235-4] [Reference Citation Analysis]
420 Qi WX, Shen Z, Tang LN, Yao Y. Does the addition of targeted biological agents to first-line chemotherapy for advanced colorectal cancer increase complete response? A systematic review and meta-analysis. Colorectal Dis 2014;16:O300-7. [PMID: 24766530 DOI: 10.1111/codi.12647] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
421 Kee BK, Morris JS, Slack RS, Crocenzi T, Wong L, Esparaz B, Overman M, Glover K, Jones D, Wen S, Fisch MJ. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer 2015;23:661-70. [PMID: 25160493 DOI: 10.1007/s00520-014-2402-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
422 Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014; 20(30): 10316-10330 [PMID: 25132748 DOI: 10.3748/wjg.v20.i30.10316] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
423 Marques AM, Turner A, de Mello RA. Personalizing medicine for metastatic colorectal cancer: Current developments. World J Gastroenterol 2014; 20(30): 10425-10431 [PMID: 25132758 DOI: 10.3748/wjg.v20.i30.10425] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
424 Patel JN, O'Neil BH, Deal AM, Ibrahim JG, Sherrill GB, Olajide OA, Atluri PM, Inzerillo JJ, Chay CH, McLeod HL, Walko CM. A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. Oncologist 2014;19:959-65. [PMID: 25117066 DOI: 10.1634/theoncologist.2014-0132] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
425 De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9732-9743 [PMID: 25110411 DOI: 10.3748/wjg.v20.i29.9732] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
426 Jeong WJ, Cha PH, Choi KY. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9862-9871 [PMID: 25110417 DOI: 10.3748/wjg.v20.i29.9862] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
427 Fakih M. SIR-Spheres ® radioembolization in the management of metastatic colorectal cancer: a medical oncology perspective. Colorectal Cancer 2014;3:331-43. [DOI: 10.2217/crc.14.29] [Reference Citation Analysis]
428 Tsunedomi R, Hazama S, Fujita Y, Okayama N, Kanekiyo S, Inoue Y, Yoshino S, Yamasaki T, Suehiro Y, Oba K, Mishima H, Sakamoto J, Hamamoto Y, Oka M. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Oncol 2014;45:1381-90. [PMID: 25175642 DOI: 10.3892/ijo.2014.2556] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
429 Giordano G, Febbraro A, Venditti M, Campidoglio S, Olivieri N, Raieta K, Parcesepe P, Imbriani GC, Remo A, Pancione M. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterol Res Pract. 2014;2014:526178. [PMID: 25136356 DOI: 10.1155/2014/526178] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
430 Znojek P, Willmore E, Curtin NJ. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br J Cancer 2014;111:1319-26. [PMID: 25003660 DOI: 10.1038/bjc.2014.378] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
431 Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist. World J Gastroenterol 2014; 20(24): 7602-7621 [PMID: 24976699 DOI: 10.3748/wjg.v20.i24.7602] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
432 Roy A, Tesauro C, Frøhlich R, Hede MS, Nielsen MJ, Kjeldsen E, Bonven B, Stougaard M, Gromova I, Knudsen BR. Decreased camptothecin sensitivity of the stem-cell-like fraction of Caco2 cells correlates with an altered phosphorylation pattern of topoisomerase I. PLoS One 2014;9:e99628. [PMID: 24960044 DOI: 10.1371/journal.pone.0099628] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
433 Ahmed S, Johnson K, Ahmed O, Iqbal N. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis 2014;29:1031-42. [PMID: 24953060 DOI: 10.1007/s00384-014-1928-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
434 Tang W, Su G, Li J, Liao J, Chen S, Huang C, Liu F, Chen Q, Ye Y. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo. Int J Oncol 2014;45:995-1010. [PMID: 24968890 DOI: 10.3892/ijo.2014.2513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
435 Vargas GM, Parmar AD, Sheffield KM, Tamirisa NP, Brown KM, Riall TS. Impact of liver-directed therapy in colorectal cancer liver metastases. J Surg Res 2014;191:42-50. [PMID: 24990539 DOI: 10.1016/j.jss.2014.05.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
436 Mhaidat NM, Bouklihacene M, Thorne RF. 5-Fluorouracil-induced apoptosis in colorectal cancer cells is caspase-9-dependent and mediated by activation of protein kinase C-δ. Oncol Lett 2014;8:699-704. [PMID: 25013487 DOI: 10.3892/ol.2014.2211] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
437 Wang SC, D’angelica MI. Chemotherapy-Associated Hepatotoxicity and Hepatic Resection for Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 2014;10:195-203. [DOI: 10.1007/s11888-014-0218-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
438 Dreosti LM, McMaster A, Mothilal R. A postauthorization survey to document the therapeutic management of oxaliplatin as a first-line chemotherapy regimen in South Africa in patients with metastatic colorectal cancer. Chemother Res Pract 2014;2014:520701. [PMID: 24818022 DOI: 10.1155/2014/520701] [Reference Citation Analysis]
439 Kim B, Park SJ, Cheon JH, Kim TI, Kim WH, Hong SP. Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer. World J Gastroenterol 2014; 20(15): 4370-4376 [PMID: 24764675 DOI: 10.3748/wjg.v20.i15.4370] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
440 Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, Wilson RH, Jasani B, Taylor GR, Williams GT. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? Br J Cancer. 2014;110:2178-2186. [PMID: 24743706 DOI: 10.1038/bjc.2014.182] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
441 Johnston PG. Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era. Oncologist 2014;19:568-73. [PMID: 24718513 DOI: 10.1634/theoncologist.2014-038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
442 Ohmura Y, Kumano K, Watanabe S, Tabuchi Y, Mitsuoka N, Watanabe T. Complete response of multiple unresectable liver metastases from ascending colon cancer treated with FOLFIRI plus bevacizumab as third-line treatment. Int Canc Conf J 2014;3:81-86. [DOI: 10.1007/s13691-013-0120-z] [Reference Citation Analysis]
443 Xu Y, Qi J, Yang X, Wu E, Qian SY. Free radical derivatives formed from cyclooxygenase-catalyzed dihomo-γ-linolenic acid peroxidation can attenuate colon cancer cell growth and enhance 5-fluorouracil's cytotoxicity. Redox Biol 2014;2:610-8. [PMID: 25114837 DOI: 10.1016/j.redox.2014.01.022] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
444 Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32:1031-1039. [PMID: 24590654 DOI: 10.1200/jco.2013.51.1857] [Cited by in Crossref: 161] [Cited by in F6Publishing: 170] [Article Influence: 17.9] [Reference Citation Analysis]
445 Matsuda Y, Shinji S, Yoshimura H, Naito Z, Ishiwata T. Fibroblast Growth Factor Receptor-2 IIIc as a Novel Molecular Target in Colorectal Cancer. Curr Colorectal Cancer Rep 2014;10:20-26. [DOI: 10.1007/s11888-013-0200-7] [Reference Citation Analysis]
446 Touchefeu Y, Archambeaud I, Landi B, Lièvre A, Lepère C, Rougier P, Mitry E. Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. Dig Liver Dis 2014;46:283-6. [PMID: 24268567 DOI: 10.1016/j.dld.2013.10.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
447 Kurniali PC, Hrinczenko B, Al-Janadi A. Management of locally advanced and metastatic colon cancer in elderly patients. World J Gastroenterol 2014; 20(8): 1910-1922 [PMID: 24616568 DOI: 10.3748/wjg.v20.i8.1910] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
448 Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: Where to fit the target? World J Gastroenterol 2014; 20(8): 1993-2004 [PMID: 24616571 DOI: 10.3748/wjg.v20.i8.1993] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
449 Lee J, Shin SJ, Chung IJ, Kim TW, Chun HG, Shin DB, Kim YH, Song HS, Han SW, Kim JG, Kim SY, Choi YJ, Chung HC. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Invest New Drugs 2014;32:561-8. [PMID: 24573743 DOI: 10.1007/s10637-014-0075-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
450 Martin LK, Bekaii-saab T. Controversies in Chemotherapy in Advanced Colorectal Cancer. Colorectal Cancer 2014. [DOI: 10.1002/9781118337929.ch14] [Reference Citation Analysis]
451 Saxena A, Chua TC, Chu FC, Ng KM, Herle P, Morris DL. Impact of treatment modality and number of lesions on recurrence and survival outcomes after treatment of colorectal cancer liver metastases. J Gastrointest Oncol 2014;5:46-56. [PMID: 24490042 DOI: 10.3978/j.issn.2078-6891.2013.055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
452 Vargas GM, Sheffield KM, Parmar AD, Han Y, Gajjar A, Brown KM, Riall TS. Trends in treatment and survival in older patients presenting with stage IV colorectal cancer. J Gastrointest Surg 2014;18:369-77. [PMID: 24234244 DOI: 10.1007/s11605-013-2406-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
453 Gil Delgado M, Delgado FM, Khayat D. Role of aflibercept in the treatment of advanced colorectal cancer. Colorectal Cancer 2014;3:27-40. [DOI: 10.2217/crc.13.78] [Reference Citation Analysis]
454 De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, D' Andrea M, Buonadonna A, Zagonel V, Cecchin E, Innocenti F, Toffoli G. Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS One 2014;9:e84940. [PMID: 24497922 DOI: 10.1371/journal.pone.0084940] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
455 Huber HJ, McKiernan RG, Prehn JH. Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches? J Mol Med (Berl) 2014;92:227-37. [PMID: 24477766 DOI: 10.1007/s00109-014-1126-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
456 Huang Y, Yu H, Lei H, Xie C, Zhong Y. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients. Med Oncol 2014;31:824. [PMID: 24469951 DOI: 10.1007/s12032-013-0824-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
457 Chung FH, Chiang YR, Tseng AL, Sung YC, Lu J, Huang MC, Ma N, Lee HC. Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma. PLoS One. 2014;9:e86299. [PMID: 24475102 DOI: 10.1371/journal.pone.0086299] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
458 Engelmann BE, Loft A, Kjær A, Nielsen HJ, Gerds TA, Benzon EV, Brünner N, Christensen IJ, Hansson SH, Holländer NH, Kristensen MH, Löfgren J, Markova E, Sloth C, Højgaard L. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer. Oncologist 2014;19:164-72. [PMID: 24451199 DOI: 10.1634/theoncologist.2013-0229] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
459 Yoshita H, Hosokawa A, Ueda A, Ando T, Kajiura S, Kato H, Kawabe H, Tomizawa G, Horikawa N, Yabuhita K, Note M, Sugiyama T. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases. Digestion 2014;89:43-8. [PMID: 24458112 DOI: 10.1159/000356218] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
460 Kim G, Jung EJ, Ryu CG, Hwang DY. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer. Yonsei Med J 2013;54:116-22. [PMID: 23225807 DOI: 10.3349/ymj.2013.54.1.116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
461 Zheng Z, Hanna N, Onukwugha E, Reese ES, Seal B, Mullins CD. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Med 2014;3:124-33. [PMID: 24403130 DOI: 10.1002/cam4.176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
462 Zhang B, Zhang B, Chen X, Bae S, Singh K, Washington MK, Datta PK. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br J Cancer. 2014;110:946-957. [PMID: 24384683 DOI: 10.1038/bjc.2013.789] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 8.0] [Reference Citation Analysis]
463 Brücher BLDM, Itzhak A, Bilchik A, Nissan A, Stojadinovic A. Carcinomatosis: Cytoreduction and Heated Intraperitoneal Chemotherapy (HIPEC) Versus Palliation. Complexities in Colorectal Surgery 2014. [DOI: 10.1007/978-1-4614-9022-7_5] [Reference Citation Analysis]
464 Hayes TK, Stratford JK, Wang-gillam A, Der CJ. RAS Genes and Cancer. Ras Superfamily Small G Proteins: Biology and Mechanisms 1 2014. [DOI: 10.1007/978-3-7091-1806-1_7] [Reference Citation Analysis]
465 Radhakrishna G, Sebag-montefiore D. Adjuvant therapy for colorectal cancer. Colorectal Surgery 2014. [DOI: 10.1016/b978-0-7020-4965-1.00006-8] [Reference Citation Analysis]
466 Kim JH, Park SJ, Park MI, Moon W, Kim SE, Ku KH, Song SE, Kim JH. FOLFIRI as Second-line Chemotherapy after Failure of FOLFOX4 in Advanced Colorectal Cancer: A Korean Single-center Experience. Korean J Gastroenterol 2014;63:18. [DOI: 10.4166/kjg.2014.63.1.18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
467 Martin Czejka, Andreas Kiss, Eva Ostermann, Johannes Schueller, Mansoor Ahmed, Najia Mansoor, Tasneem Ahmad. Metabolic Activation and Inactivation of Irinotecan when Combined with the Human Monoclonal Antibody Bevacizumab. J Anal Oncol 2013;2. [DOI: 10.6000/1927-7229.2013.02.04.4] [Reference Citation Analysis]
468 Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer. 2013;13:611. [PMID: 24373251 DOI: 10.1186/1471-2407-13-611] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
469 Perchiniak EM, Groden J. Colon and rectal cancer. Molecular Oncology 2013. [DOI: 10.1017/cbo9781139046947.048] [Reference Citation Analysis]
470 Redman MW, Goldman BH, LeBlanc M, Schott A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res 2013;19:2646-56. [PMID: 23669424 DOI: 10.1158/1078-0432.CCR-12-2939] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
471 Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, Hebbar M, Fan F, Ellis LM, Formstecher P, Van Seuningen I, Gespach C, Polakowska R, Huet G. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res 2014;20:837-46. [PMID: 24323901 DOI: 10.1158/1078-0432.CCR-13-1854] [Cited by in Crossref: 184] [Cited by in F6Publishing: 204] [Article Influence: 18.4] [Reference Citation Analysis]
472 Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics 2012;30:1119-32. [PMID: 23058097 DOI: 10.2165/11597210-000000000-00000] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
473 Patel V, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2013;17:533-46, vii. [PMID: 24099016 DOI: 10.1016/j.cld.2013.07.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
474 Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci 2013;104:1662-9. [PMID: 24033692 DOI: 10.1111/cas.12283] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
475 Zhou Y, Bollu LR, Tozzi F, Ye X, Bhattacharya R, Gao G, Dupre E, Xia L, Lu J, Fan F, Bellister S, Ellis LM, Weihua Z. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Mol Cancer Ther 2013;12:2782-91. [PMID: 24132143 DOI: 10.1158/1535-7163.MCT-13-0098] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 5.7] [Reference Citation Analysis]
476 Reese ES, Onukwugha E, Hanna N, Seal BS, Mullins CD. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. Cancer Med 2013;2:907-15. [PMID: 24403264 DOI: 10.1002/cam4.143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
477 Cross-Knorr S, Lu S, Perez K, Guevara S, Brilliant K, Pisano C, Quesenberry PJ, Resnick MB, Chatterjee D. RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. BMC Cancer 2013;13:463. [PMID: 24098947 DOI: 10.1186/1471-2407-13-463] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
478 Louie SG, Ely B, Lenz HJ, Albain KS, Gotay C, Coleman D, Raghavan D, Shields AF, Gold PJ, Blanke CD. Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). Br J Cancer 2013;109:1744-9. [PMID: 24022189 DOI: 10.1038/bjc.2013.517] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
479 Patel GS, Jain K, Kumar R, Strickland AH, Pellegrini L, Slavotinek J, Eaton M, McLeay W, Price T, Ly M, Ullah S, Koczwara B, Kichenadasse G, Karapetis CS. Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. Support Care Cancer 2014;22:121-8. [PMID: 24005884 DOI: 10.1007/s00520-013-1941-1] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 7.1] [Reference Citation Analysis]
480 Luu C, Arrington AK, Schoellhammer HF, Singh G, Kim J. Targeted therapies in colorectal cancer: surgical considerations. J Gastrointest Oncol 2013;4:328-36. [PMID: 23997944 DOI: 10.3978/j.issn.2078-6891.2013.032] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
481 Jenab-wolcott J, Giantonio B. The Continuum of Care in Chemotherapy Approach to Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 2013;9:230-241. [DOI: 10.1007/s11888-013-0178-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
482 Antonieta Salud, Vicente Alonso, Pilar Escudero, Miguel Burillo, Cristina Martín, Fernando Rivera, Alfonso Yubero, Carlos García-girón, Alberto Muñoz. Phase II Study of Irinotecan in Combination with Capecitabine on a 3-Weekly Schedule as First-Line Chemotherapy for Patients with Metastatic or Locally Advanced Colorectal Cancer. J Anal Oncol 2013;2. [DOI: 10.6000/1927-7229.2013.02.03.4] [Reference Citation Analysis]
483 Amano R, Yamada N, Nakata B, Kimura K, Yashiro M, Ohira M, Hirakawa K. Prognostic indicator for the resection of liver metastasis of colorectal cancer. Surg Today 2014;44:1287-92. [PMID: 23979110 DOI: 10.1007/s00595-013-0699-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
484 Shi Q, Andre T, Grothey A, Yothers G, Hamilton SR, Bot BM, Haller DG, Van Cutsem E, Twelves C, Benedetti JK, O'Connell MJ, Sargent DJ. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. J Clin Oncol. 2013;31:3656-3663. [PMID: 23980089 DOI: 10.1200/jco.2013.49.4344] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
485 Wulaningsih W, Wardhana A, Yoshuantari N, Sekarini AA, Van Hemelrijck M. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer. Cochrane Database of Systematic Reviews 2013. [DOI: 10.1002/14651858.cd008593.pub2] [Reference Citation Analysis]
486 Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6:988-1038. [PMID: 24276379 DOI: 10.3390/ph6080988] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
487 Leo S, Accettura C, Gnoni A, Licchetta A, Giampaglia M, Mauro A, Saracino V, Carr BI. Systemic treatment of gastrointestinal cancer in elderly patients. J Gastrointest Cancer. 2013;44:22-32. [PMID: 23150086 DOI: 10.1007/s12029-012-9447-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
488 Cai X, Cao W, Ding H, Liu T, Zhou X, Wang M, Zhong M, Zhao Z, Xu Q, Wang L. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. J Cancer Res Clin Oncol. 2013;139:1579-1589. [PMID: 23892411 DOI: 10.1007/s00432-013-1480-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
489 Lim HJ, Gill S, Speers C, Melosky B, Barnett J, Fitzgerald C, O'Reilly S, Kennecke H. Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study. J Oncol Pract 2009;5:153-8. [PMID: 20856627 DOI: 10.1200/JOP.0942001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
490 Tezuka T, Hamada C, Ishida H, Ooshiro M, Matsuoka H, Kawasaki S, Mishima H, Maeda K, Sakamoto J, Koda K. Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study. Invest New Drugs. 2013;31:1321-1329. [PMID: 23817973 DOI: 10.1007/s10637-013-9982-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
491 Kobayashi H, Kotake K, Funahashi K, Hase K, Hirata K, Iiai T, Kameoka S, Kanemitsu Y, Maeda K, Murata A. Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis. J Gastroenterol. 2014;49:646-654. [PMID: 23793379 DOI: 10.1007/s00535-013-0820-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
492 de la Cueva A, Ramírez de Molina A, Alvarez-Ayerza N, Ramos MA, Cebrián A, Del Pulgar TG, Lacal JC. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One. 2013;8:e64961. [PMID: 23762272 DOI: 10.1371/journal.pone.0064961] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
493 Losa F, Barrios P, Salazar R, Torres-melero J, Benavides M, Massuti T, Ramos I, Aranda E. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin Transl Oncol 2014;16:128-40. [DOI: 10.1007/s12094-013-1053-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
494 Arakawa Y, Shimada M, Utsunomya T, Imura S, Morine Y, Ikemoto T, Hanaoka J, Sugimoto K, Bando Y. Oxaliplatin-related sinusoidal obstruction syndrome mimicking metastatic liver tumors. Hepatol Res 2013;43:685-9. [PMID: 23730707 DOI: 10.1111/j.1872-034X.2012.01114.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
495 Loupakis F, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, Cremolini C, Salvatore L, Morvillo M, Antoniotti C, Marmorino F, Masi G, Falcone A. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 2013;108:2549-56. [PMID: 23703247 DOI: 10.1038/bjc.2013.245] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
496 Shao YC, Chang YY, Lin JK, Lin CC, Wang HS, Yang SH, Jiang JK, Lan YT, Lin TC, Li AF. Neoadjuvant chemotherapy can improve outcome of colorectal cancer patients with unresectable metastasis. Int J Colorectal Dis. 2013;28:1359-1365. [PMID: 23695387 DOI: 10.1007/s00384-013-1713-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
497 Grande R, Gemma D, Sperduti I, Gelibter A, Giampaolo MA, Trombetta G, Nelli F, Gamucci T. Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained? Springerplus 2013;2:185. [PMID: 23667824 DOI: 10.1186/2193-1801-2-185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
498 Eveno C, Karoui M, Gayat E, Luciani A, Auriault ML, Kluger MD, Baumgaertner I, Baranes L, Laurent A, Tayar C, Azoulay D, Cherqui D. Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections. HPB (Oxford) 2013;15:359-64. [PMID: 23458567 DOI: 10.1111/j.1477-2574.2012.00581.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
499 Kim YW, Kim IY. The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer. Ann Coloproctol 2013;29:44-54. [PMID: 23700570 DOI: 10.3393/ac.2013.29.2.44] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
500 Kim YW, Kim IY. The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer. Ann Coloproctol 2013;29:44-54. [PMID: 23700570 DOI: 10.3393/ac.2013.29.2.44] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
501 Shionome Y, Lin WH, Shiao HY, Hsieh HP, Hsu JT, Ouchi T. A novel aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment. Int J Biol Sci 2013;9:403-11. [PMID: 23678290 DOI: 10.7150/ijbs.5806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
502 Sirohi B, Philip DS, Shrikhande SV. Regorafenib: carving a niche in the crowded therapeutic landscape. Expert Rev Anticancer Ther 2013;13:385-93. [PMID: 23560833 DOI: 10.1586/era.13.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
503 Watanabe M, Sowa Y, Yogosawa M, Sakai T. Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci 2013;104:687-93. [PMID: 23438367 DOI: 10.1111/cas.12139] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
504 Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J. 2013;Epub ahead of print. [PMID: 23529007 DOI: 10.1038/tpj.2013.10] [Cited by in Crossref: 95] [Cited by in F6Publishing: 105] [Article Influence: 9.5] [Reference Citation Analysis]
505 Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol. 2013;24:1560-1567. [PMID: 23493136 DOI: 10.1093/annonc/mdt056] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 5.9] [Reference Citation Analysis]
506 Nguyen-Khac E, Lobry C, Chatelain D, Fuks D, Joly JP, Brevet M, Tramier B, Mouly C, Hautefeuille V, Chauffert B, Regimbeau JM. A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics. Int J Hepatol 2013;2013:314868. [PMID: 23533786 DOI: 10.1155/2013/314868] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
507 Huang L, Liao X, Yu Q, Fu Q, Qin K, Wu H, Zhang L, Yuan X. Common toxicities and objective response rate in metastatic colorectal cancer patients treated with irinotecan based regimens. Chin -Ger J Clin Oncol 2013;12:109-112. [DOI: 10.1007/s10330-013-1142-x] [Reference Citation Analysis]
508 Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 2013;7:637-646. [PMID: 23506979 DOI: 10.1016/j.molonc.2013.02.016] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 6.6] [Reference Citation Analysis]
509 Murono K, Kawai K, Kazama S, Tsuno NH, Sunami E, Kitayama J, Watanabe T. Colorectal cancer with multiple metachronous metastasis achieving complete remission 14 years after surgical resection: report of a case. Int Surg 2013;98:49-54. [PMID: 23438276 DOI: 10.9738/CC172.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
510 Lubner SJ, Kim D, Weiss J. Colorectal and Anal Tumors: An Oncologist's Perspective. Gastrointestinal Endoscopy in the Cancer Patient 2013. [DOI: 10.1002/9781118555651.ch28] [Reference Citation Analysis]
511 Ogata Y, Tanaka T, Akagi Y, Ishibashi N, Tsuji Y, Matono K, Isobe M, Sueyoshi S, Kaibara A, Shirouzu K. Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer. Clin Med Insights Oncol. 2013;7:21-30. [PMID: 23439317 DOI: 10.4137/CMO.S10769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
512 Glockzin G, Rochon J, Arnold D, Lang SA, Klebl F, Zeman F, Koller M, Schlitt HJ, Piso P. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer. 2013;13:67. [PMID: 23391248 DOI: 10.1186/1471-2407-13-67] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
513 Wahba HA, El-Hadaad HA, Roshdy S. Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma. J Gastrointest Cancer 2012;43:467-71. [PMID: 22147447 DOI: 10.1007/s12029-011-9350-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
514 Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:53-58. [PMID: 23378775 DOI: 10.2147/ott.s41383] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
515 Yi BR, Park MA, Lee HR, Kang NH, Choi KJ, Kim SU, Choi KC. Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models. Mol Oncol 2013;7:543-54. [PMID: 23403306 DOI: 10.1016/j.molonc.2013.01.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
516 Troiani T, Martinelli E, Morgillo F, Capasso A, Nappi A, Sforza V, Ciardiello F. Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? Ther Adv Med Oncol 2013;5:51-72. [PMID: 23323147 DOI: 10.1177/1758834012462462] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
517 Liu X, Cao Z, Mendoza J, Vardeman D, Giovanella B. Correlation between the sensitivity of tumors to treatment with CZ48 and local concentrations of the active metabolite CPT within the tumors. Biomed Rep 2013;1:202-6. [PMID: 24648919 DOI: 10.3892/br.2013.55] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
518 Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Invest New Drugs 2013;31:845-57. [PMID: 23299388 DOI: 10.1007/s10637-012-9914-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
519 Wang CZ, Li B, Wen XD, Zhang Z, Yu C, Calway TD, He TC, Du W, Yuan CS. Paraptosis and NF-κB activation are associated with protopanaxadiol-induced cancer chemoprevention. BMC Complement Altern Med 2013;13:2. [PMID: 23281928 DOI: 10.1186/1472-6882-13-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
520 de Gramont A. Post-face Vers une nouvelle recherche adaptée à une médecine personnalisée. Médecine personnalisée en cancérologie digestive 2013. [DOI: 10.1007/978-2-8178-0527-6_28] [Reference Citation Analysis]
521 Boisdron-celle M, Guérin-meyer V, Capitain O. 5-fluorouracile : MSI, pharmacocinétique, DPD, TYMS et MTHFR. Médecine personnalisée en cancérologie digestive 2013. [DOI: 10.1007/978-2-8178-0527-6_6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
522 Gencer D. Kombination von Zytostatika mit Strahlentherapie: Radiochemotherapie. Strahlentherapie 2013. [DOI: 10.1007/978-3-540-88305-0_12] [Reference Citation Analysis]
523 Barreto Andrade JC, Posner MC, Roggin KK. Management of Secondary Hepatic Neoplasms. Shackelford's Surgery of the Alimentary Tract 2013. [DOI: 10.1016/b978-1-4377-2206-2.00130-5] [Reference Citation Analysis]
524 Inada R, Nagasaka T, Mori Y, Umeda Y, Kubota N, Morikawa T, Kondo Y, Uno F, Sadamori Y, Yagi T, Fujiwara T. A successful rechallenge with cetuximab for a case with metastatic rectal cancer. Okayama I Z 2013;125:51-55. [DOI: 10.4044/joma.125.51] [Reference Citation Analysis]
525 Ikeda M, Sekimoto M, Takemasa I, Mizushima T, Yamamoto H, Ishii H, Doki Y, Mori M. Feasibility and Efficacy Study of Biweekly Irinotecan Combined with Oral Tegafur/Uracil in Advanced Colorectal Cancer. JCT 2013;04:8-14. [DOI: 10.4236/jct.2013.46a2002] [Reference Citation Analysis]
526 Katayama Y, Shiozawa M, Sawazaki S, Numata K, Numata M, Higuchi A, Godai T, Rino Y, Masuda M, Makoto A. Prognostic Factors of Patients Who Underwent Primary Tumor Resection in Stage IV Colorectal Cancer with Non-resectable Synchronous Metastasis. Journal of Japan Society of Coloproctology 2013;66:585-590. [DOI: 10.3862/jcoloproctology.66.585] [Reference Citation Analysis]
527 Gerger A, Labonte MJ, Lenz H. Predictive Markers in Colon Cancer. Biomarkers in Oncology 2013. [DOI: 10.1007/978-1-4419-9755-5_1] [Reference Citation Analysis]
528 Pedone KH, Sells JL, Der CJ. Mutational Activation of KRAS and BRAF in Colorectal Cancer. Molecular Pathogenesis of Colorectal Cancer 2013. [DOI: 10.1007/978-1-4614-8412-7_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
529 Mino M, Homicsko K, Stupp R. Central Nervous System. Side Effects of Medical Cancer Therapy 2013. [DOI: 10.1007/978-0-85729-787-7_7] [Reference Citation Analysis]
530 Weiser MR, Posner MC, Saltz LB. Adenocarcinoma of the Colon and Rectum. Shackelford's Surgery of the Alimentary Tract 2013. [DOI: 10.1016/b978-1-4377-2206-2.00164-0] [Reference Citation Analysis]
531 Glimelius B. Palliation and Quality of Life. Management of Colorectal Cancers in Older People 2013. [DOI: 10.1007/978-0-85729-984-0_13] [Reference Citation Analysis]
532 Solanki AA, Weichselbaum RR, Appelbaum D, Farrey K, Yenice KM, Chmura SJ, Salama JK. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol 2012;7:216. [PMID: 23244066 DOI: 10.1186/1748-717X-7-216] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
533 Jourabchi N, Sauk S, Hoffman C, Lee EW, Kee ST. Intercostal artery pseudoaneurysm formation after irinotecan transarterial chemoembolization of a spinal metastasis from colorectal cancer. Case Rep Radiol 2012;2012:146540. [PMID: 23316405 DOI: 10.1155/2012/146540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
534 Ahmed S, Eng C. Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer. Curr Colorectal Cancer Rep 2012;8:233-242. [DOI: 10.1007/s11888-012-0138-1] [Reference Citation Analysis]
535 Audisio RA, Papamichael D. Treatment of colorectal cancer in older patients. Nat Rev Gastroenterol Hepatol 2012;9:716-25. [PMID: 23045000 DOI: 10.1038/nrgastro.2012.196] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
536 Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, Joh T. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol 2013;139:367-78. [PMID: 23099994 DOI: 10.1007/s00432-012-1340-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
537 Guan S. Statistical Designs for Early Phases of Cancer Clinical Trials. Journal of Biopharmaceutical Statistics 2012;22:1109-26. [DOI: 10.1080/10543406.2011.571801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
538 Ligabue A, Marverti G, Liebl U, Myllykallio H. Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression. PLoS One 2012;7:e47318. [PMID: 23056627 DOI: 10.1371/journal.pone.0047318] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
539 Burotto M, Hartley ML, Marshall JL, Pishvaian MJ. Future of targeted agents in metastatic colorectal cancer. Colorectal Cancer 2012;1. [PMID: 24273599 DOI: 10.2217/crc.12.52] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
540 허훈, 임현정, 정선영, 박영석, 인용원, 이영미, 최지선. Hypertension and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with Bevacizumab. journalofkoreansocietyofhealthsystempharmacists 2012;29:324-337. [DOI: 10.32429/jkshp.2012.29.3.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
541 Cremolini C, Loupakis F, Antoniotti C, Salvatore L, Schirripa M, Fornaro L, Masi G, Falcone A. Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics? Curr Colorectal Cancer Rep 2012;8:153-160. [DOI: 10.1007/s11888-012-0128-3] [Reference Citation Analysis]
542 Pascal G, Laurent A, Azoulay D. Strategia oncochirurgica di gestione delle metastasi epatiche di origine colorettale. EMC - Tecniche Chirurgiche Addominale 2012;18:1-9. [DOI: 10.1016/s1283-0798(12)62078-6] [Reference Citation Analysis]
543 Ferrarotto R, Sabbaga J, Capareli FC, Saragiotto DF, Hoff PM. Best Strategy in the Approach of Advanced Colorectal Cancer: Aggressive or Non-aggressive Chemotherapy? Curr Colorectal Cancer Rep 2012;8:177-185. [DOI: 10.1007/s11888-012-0131-8] [Reference Citation Analysis]
544 Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:75-89. [PMID: 22423266 DOI: 10.1177/1758834011431592] [Cited by in Crossref: 50] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
545 Vonk DT, Hazard LJ. Do all locally advanced rectal cancers require radiation? A review of literature in the modern era. J Gastrointest Oncol. 2010;1:45-54. [PMID: 22811804 DOI: 10.3978/j.issn.2078-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
546 Frank D, Jumonville A, Loconte NK, Schelman WR, Mulkerin D, Lubner S, Richter K, Winterle N, Wims MB, Dietrich L, Winkler JM, Volk M, Kim K, Holen KD. A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study. J Gastrointest Oncol 2012;3:90-6. [PMID: 22811876 DOI: 10.3978/j.issn.2078-6891.2011.049] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
547 Munireddy S, Katz S, Somasundar P, Espat NJ. Thermal tumor ablation therapy for colorectal cancer hepatic metastasis. J Gastrointest Oncol 2012;3:69-77. [PMID: 22811871 DOI: 10.3978/j.issn.2078-6891.2012.008] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
548 Solier S, Zhang YW, Ballestrero A, Pommier Y, Zoppoli G. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. Curr Cancer Drug Targets 2012;12:356-71. [PMID: 22385513 DOI: 10.2174/156800912800190901] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
549 Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, Chatelut E, Francois E, Faroux R, El Hannani C. Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol. 2012;73:776-785. [PMID: 22486600 DOI: 10.1111/j.1365-2125.2011.04141.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
550 Pascal G, Laurent A, Azoulay D. Estrategia terapéutica oncoquirúrgica de las metástasis hepáticas de origen colorrectal. EMC - Técnicas Quirúrgicas - Aparato Digestivo 2012;28:1-10. [DOI: 10.1016/s1282-9129(12)62678-6] [Reference Citation Analysis]
551 Kim JH, Kim HS, Choi DR, Jang G, Kwon JH, Kim HY, Jung JY, Kim HJ, Song HH, Shin YH, Jung SY, Kim BC, Zang DY. A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer. Oncol Lett 2011;2:1253-6. [PMID: 22848297 DOI: 10.3892/ol.2011.367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
552 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T, Kishine K, Ochi T, Okubo S, Futagawa S, Mashiko S, Nagaoka I. Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett 2012;4:621-4. [PMID: 23205073 DOI: 10.3892/ol.2012.823] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
553 Kobayashi M, Hazama S, Takahashi K, Oba K, Okayama N, Nishioka M, Hinoda Y, Oka M, Okamoto K, Maeda H, Nakamura D, Sakamoto J, Mishima H. Is there diversity among UGT1A1 polymorphism in Japan. World J Gastrointest Oncol 2012; 4(7): 170-175 [PMID: 22848786 DOI: 10.4251/wjgo.v4.i7.170] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
554 Manne U, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE. Development and progression of colorectal neoplasia. Cancer Biomark. 2010;9:235-265. [PMID: 22112479 DOI: 10.3233/cbm-2011-0160] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
555 Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Invest New Drugs. 2013;31:183-191. [PMID: 22782485 DOI: 10.1007/s10637-012-9853-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
556 Li X, Liu S, Gu H, Wang D. Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. J Cancer Res Clin Oncol 2012;138:1963-9. [PMID: 22763646 DOI: 10.1007/s00432-012-1278-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
557 Choi KY, Jeon EJ, Yoon HY, Lee BS, Na JH, Min KH, Kim SY, Myung SJ, Lee S, Chen X, Kwon IC, Choi K, Jeong SY, Kim K, Park JH. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials 2012;33:6186-93. [PMID: 22687759 DOI: 10.1016/j.biomaterials.2012.05.029] [Cited by in Crossref: 115] [Cited by in F6Publishing: 121] [Article Influence: 10.5] [Reference Citation Analysis]
558 Kajizono M, Saito M, Maeda M, Yamaji K, Fujiwara S, Kawasaki Y, Matsunaga H, Sendo T. Cetuximab-induced skin reactions are suppressed by cigarette smoking in patients with advanced colorectal cancer. Int J Clin Oncol 2013;18:684-8. [PMID: 22678464 DOI: 10.1007/s10147-012-0427-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
559 Allen WL, Turkington RC, Stevenson L, Carson G, Coyle VM, Hector S, Dunne P, Van Schaeybroeck S, Longley DB, Johnston PG. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells. Mol Cancer Ther 2012;11:1724-34. [PMID: 22665525 DOI: 10.1158/1535-7163.MCT-12-0207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
560 Strassburg CP, Kalthoff S. UDP-Glucuronosyltransferases. Metabolism of Drugs and Other Xenobiotics 2012. [DOI: 10.1002/9783527630905.ch3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
561 Nishigori H, Ito M, Nishizawa Y, Kohyama A, Koda T, Nakajima K, Nishizawa Y, Kobayashi A, Sugito M, Saito N. Laparoscopic surgery for palliative resection of the primary tumor in incurable stage IV colorectal cancer. Surg Endosc. 2012;26:3201-3206. [PMID: 22648097 DOI: 10.1007/s00464-012-2323-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
562 Janne d'Othée B, Sofocleous CT, Hanna N, Lewandowski RJ, Soulen MC, Vauthey JN, Cohen SJ, Venook AP, Johnson MS, Kennedy AS, Murthy R, Geschwind JF, Kee ST. Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol 2012;23:153-63. [PMID: 22264550 DOI: 10.1016/j.jvir.2011.12.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
563 Tsushima T, Taguri M, Honma Y, Takahashi H, Ueda S, Nishina T, Kawai H, Kato S, Suenaga M, Tamura F. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist. 2012;17:1163-1170. [PMID: 22622149 DOI: 10.1634/theoncologist.2012-0079] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
564 Lima JP, de Souza FH, de Andrade DA, Carvalheira JB, dos Santos LV. Independent radiologic review in metastatic colorectal cancer: systematic review and meta-analysis. Radiology 2012;263:86-95. [PMID: 22438443 DOI: 10.1148/radiol.11111111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
565 Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y, Ogawa M, Ishida Y, Misawa T, Yanaga K. The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett. 2012;4:324-328. [PMID: 22844378 DOI: 10.3892/ol.2012.722] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
566 Brouquet A, Benoist S. Quelle stratégie thérapeutique devant un cancer du rectum avec métastases hépatiques synchrones ? Colon Rectum 2012;6:105-113. [DOI: 10.1007/s11725-012-0377-y] [Reference Citation Analysis]
567 Liu HL, Li ZY, Liu YF, Li HY, Yu ZH. Irinotecan-related cholinergic symptoms in patients with colorectal cancer patients: an analysis of 89 cases. Shijie Huaren Xiaohua Zazhi 2012; 20(11): 975-979 [DOI: 10.11569/wcjd.v20.i11.975] [Reference Citation Analysis]
568 Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D 2011;11:101-11. [PMID: 21679003 DOI: 10.2165/11590440-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
569 Turner K, Alexander HR. Cytoreduction and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis dissemination from colorectal cancer. Colorectal Cancer 2012;1:125-135. [DOI: 10.2217/crc.12.5] [Reference Citation Analysis]
570 Pascal G, Laurent A, Azoulay D. Stratégie oncochirurgicale de prise en charge des métastases hépatiques d’origine colorectale. EMC - Techniques chirurgicales - Appareil digestif 2012;7:1-9. [DOI: 10.1016/s0246-0424(12)51086-1] [Reference Citation Analysis]
571 Assy N, Basher W, Chetver L, Shnaider J, Zidan J. First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study. J Clin Gastroenterol 2012;46:e27-30. [PMID: 22392022 DOI: 10.1097/MCG.0b013e3182470f09] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
572 Viganò L, Karoui M, Ferrero A, Tayar C, Cherqui D, Capussotti L. Locally advanced mid/low rectal cancer with synchronous liver metastases. World J Surg. 2011;35:2788-2795. [PMID: 21947493 DOI: 10.1007/s00268-011-1272-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
573 López-Gómez M, Merino M, Casado E. Long-term treatment of metastatic colorectal cancer with panitumumab. Clin Med Insights Oncol 2012;6:125-35. [PMID: 22408376 DOI: 10.4137/CMO.S5055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
574 Glimelius B, Cavalli-Björkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status. Scand J Gastroenterol 2012;47:296-314. [PMID: 22242568 DOI: 10.3109/00365521.2012.640828] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
575 Brouquet A, Nordlinger B. Neoadjuvant and adjuvant therapy in relation to surgery for colorectal liver metastases. Scand J Gastroenterol 2012;47:286-95. [PMID: 22182353 DOI: 10.3109/00365521.2012.640826] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
576 Kurokawa K, Tanahashi T, Iima T, Yamamoto Y, Akaike Y, Nishida K, Masuda K, Kuwano Y, Murakami Y, Fukushima M. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol. 2012;47:883-895. [PMID: 22382630 DOI: 10.1007/s00535-012-0547-6] [Cited by in Crossref: 69] [Cited by in F6Publishing: 79] [Article Influence: 6.3] [Reference Citation Analysis]
577 Baba E, Fujishima H, Makiyama A, Uchino K, Tanaka R, Esaki T, Kusaba H, Mitsugi K, Nakano S, Akashi K. Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. Adv Ther 2012;29:287-96. [PMID: 22351434 DOI: 10.1007/s12325-012-0002-3] [Reference Citation Analysis]
578 Nam SJ, Cho JY, Lee HS, Choe G, Jang JJ, Yoon YS, Han HS, Kim H. Chemotherapy-associated hepatopathy in korean colorectal cancer liver metastasis patients: oxaliplatin-based chemotherapy and sinusoidal injury. Korean J Pathol 2012;46:22-9. [PMID: 23109974 DOI: 10.4132/KoreanJPathol.2012.46.1.22] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
579 Guérin E, Raffelsberger W, Pencreach E, Maier A, Neuville A, Schneider A, Bachellier P, Rohr S, Petitprez A, Poch O, Moras D, Oudet P, Larsen AK, Gaub MP, Guenot D. In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis. Mol Med 2012;18:83-94. [PMID: 22033674 DOI: 10.2119/molmed.2011.00120] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
580 Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, Galizia E, Loretelli C, Belvederesi L, Bittoni A, Cascinu S. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer 2012;106:799-804. [PMID: 22315053 DOI: 10.1038/bjc.2012.17] [Cited by in Crossref: 72] [Cited by in F6Publishing: 85] [Article Influence: 6.5] [Reference Citation Analysis]
581 Goéré D. Métastases hépatiques colorectales La réponse tumorale: pourquoi et comment l’évaluer ? Journal de Chirurgie Viscérale 2012;149:S6-S15. [DOI: 10.1016/s1878-786x(12)70095-5] [Reference Citation Analysis]
582 Mitsuyama Y, Shiba H, Haruki K, Fujiwara Y, Furukawa K, Iida T, Hayashi T, Ogawa M, Ishida Y, Misawa T, Kashiwagi H, Yanaga K. Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis. Oncol Lett 2012;3:767-71. [PMID: 22740990 DOI: 10.3892/ol.2012.574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
583 Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012;30:608-615. [PMID: 22253466 DOI: 10.1200/jco.2011.38.9650] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 9.1] [Reference Citation Analysis]
584 Cao S, Durrani FA, Rustum YM, Yu YE. Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity. Cancer Chemother Pharmacol 2012;69:1107-11. [PMID: 22237959 DOI: 10.1007/s00280-011-1820-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
585 Neugut AI, Becker DJ, Insel BJ, Hershman DL. Uptake of oxaliplatin and bevacizumab for treatment of node-positive and metastatic colon cancer. J Oncol Pract 2012;8:156-63. [PMID: 22942809 DOI: 10.1200/JOP.2011.000371] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
586 Tanaka T, Bai T, Toujima S, Utsunomiya T, Matsuoka T, Kobayashi A, Yamamoto M, Sasaki N, Tanizaki Y, Utsunomiya H, Tanaka J, Yukawa K. Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells. Oncol Rep 2012;27:1292-8. [PMID: 22246465 DOI: 10.3892/or.2012.1628] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
587 Zdenkowski N, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. Oncologist. 2012;17:201-211. [PMID: 22234631 DOI: 10.1634/theoncologist.2011-0300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
588 Chan KK, Wong B, Siu LL, Straus SE, Chang J, Berry SR. Less than ideal: how oncologists practice with limited drug access. J Oncol Pract 2012;8:190-5. [PMID: 22942815 DOI: 10.1200/JOP.2011.000337] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
589 Eblen ST. Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol. 2012;83:1063-1072. [PMID: 22248731 DOI: 10.1016/j.bcp.2011.12.041] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
590 Matsumura C, Nakamura N, Aomatsu Y, Kuwata H, Takayama A, Yano Y. Need for pharmaceutical care during chemotherapy for prevention of side effects: examples of blood sugar monitoring in dexamethasone treatment. Palliat Care Res 2012;7:101-111. [DOI: 10.2512/jspm.7.101] [Reference Citation Analysis]
591 Zonta A, Roveda L, Altieri S. Liver Metastases. Neutron Capture Therapy 2012. [DOI: 10.1007/978-3-642-31334-9_28] [Reference Citation Analysis]
592 Literaturhinweise und Internetadressen. Facharzt Hämatologie Onkologie 2012. [DOI: 10.1016/b978-3-437-21212-3.10048-7] [Reference Citation Analysis]
593 Winter J, Auer RAC. Metastatic malignant liver tumors. Blumgart's Surgery of the Liver, Pancreas and Biliary Tract 2012. [DOI: 10.1016/b978-1-4377-1454-8.00081-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
594 Makeyev Y, Muggia F, Rajan A, Giaccone G, Furuta T, Rougier P. Topoisomerase I Inhibitors: Current Use and Prospects. Cancer Drug Discovery and Development 2012. [DOI: 10.1007/978-1-4614-0323-4_12] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
595 Kneuertz PJ, Kooby DA. Systemic chemotherapy for hepatic colorectal cancer. Blumgart's Surgery of the Liver, Pancreas and Biliary Tract 2012. [DOI: 10.1016/b978-1-4377-1454-8.00087-4] [Reference Citation Analysis]
596 Lee W, Shiau J, Shyur L. Taxol, Camptothecin and Beyond for Cancer Therapy. Advances in Botanical Research 2012. [DOI: 10.1016/b978-0-12-394591-4.00008-8] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
597 Osterlund P, Valta P, Bondedstam S, Lindgren L. Prospective Assessment of Catheter Migration in Implanted Vascular Access Devices for Adjuvant Colorectal Cancer Chemotherapy. JCT 2012;03:920-925. [DOI: 10.4236/jct.2012.326118] [Reference Citation Analysis]
598 Nagorney DM, Grothey A. Adjuvant hepatic arterial infusional chemotherapy: revisiting the past or a new era? Ann Surg 2011;254:857-9. [PMID: 22107739 DOI: 10.1097/SLA.0b013e31823a9a98] [Reference Citation Analysis]
599 Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer 2012;106:18-24. [PMID: 22108516 DOI: 10.1038/bjc.2011.498] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 6.0] [Reference Citation Analysis]
600 Guo GF, Jiang WQ, Zhang B, Cai YC, Xu RH, Chen XX, Wang F, Xia LP. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World J Gastroenterol 2011; 17(43): 4779-4786 [PMID: 22147978 DOI: 10.3748/wjg.v17.i43.4779] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
601 Yamane H, Matsubara M, Umemura S, Suwaki T, Kamei H, Takigawa N, Kiura K, Tanimoto M. Variant angina pectoris associated with FOLFOX4 therapy. World J Gastrointest Oncol 2011; 3(11): 165-168 [PMID: 22110843 DOI: 10.4251/wjgo.v3.i11.165] [Reference Citation Analysis]
602 Grothey A. Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol 2009;1:55-68. [PMID: 21789113 DOI: 10.1177/1758834009343302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
603 Song X, Zhao Z, Barber B, Gregory C, Schutt D, Gao S. Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract 2011;7:25s-30s. [PMID: 21886516 DOI: 10.1200/JOP.2011.000304] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
604 Braun MS, Seymour MT. Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol. 2011;3:43-52. [PMID: 21789155 DOI: 10.1177/1758834010388342] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
605 Peinert S, Grothe W, Stein A, Müller LP, Ruessel J, Voigt W, Schmoll HJ, Arnold D. Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. Ther Adv Med Oncol 2010;2:161-74. [PMID: 21789132 DOI: 10.1177/1758834010365061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
606 Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 2011;20:384-99. [PMID: 21907928 DOI: 10.1016/j.ccr.2011.08.013] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 7.8] [Reference Citation Analysis]
607 Brixi-Benmansour H, Jouve JL, Mitry E, Bonnetain F, Landi B, Hentic O, Bedenne L, Cadiot G. Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. Dig Liver Dis 2011;43:912-6. [PMID: 21831734 DOI: 10.1016/j.dld.2011.07.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
608 Kambakamba P, Breitenstein S, Samaras P, Schneider PM, Lurje G. Which therapy for which patient? Pharmacological Advances in Metastatic Colorectal Cancer Management 2011. [DOI: 10.2217/ebo.11.128] [Reference Citation Analysis]
609 Hwang JE, Shim HJ, Park YK, Cho SH, Bae WK, Kim DE, Kim KK, Chung IJ. Intravenous KITENIN shRNA injection suppresses hepatic metastasis and recurrence of colon cancer in an orthotopic mouse model. J Korean Med Sci 2011;26:1439-45. [PMID: 22065899 DOI: 10.3346/jkms.2011.26.11.1439] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
610 Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, Carson G, Gordon MA, Lenz HJ, Van Schaeybroeck S, Longley DB. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Mol Cancer Ther. 2012;11:119-131. [PMID: 22027693 DOI: 10.1158/1535-7163.MCT-11-0510] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
611 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012;17:1-29. [PMID: 22002491 DOI: 10.1007/s10147-011-0315-2] [Cited by in Crossref: 528] [Cited by in F6Publishing: 583] [Article Influence: 44.0] [Reference Citation Analysis]
612 Uddin S, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma. Am J Pathol 2011;179:3032-44. [PMID: 21978492 DOI: 10.1016/j.ajpath.2011.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
613 Baba H, Hayashi N, Emi Y, Kakeji Y, Egashira A, Oki E, Shirabe K, Toyama T, Ohga T, Yamamoto M, Hasegawa H, Kohakura F, Higashi H, Niwa K, Fujita F, Ogata Y, Kohnoe S, Inomata M, Samura H, Tokunaga S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. Surg Today 2011;41:1610-6. [PMID: 21969193 DOI: 10.1007/s00595-011-4589-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
614 Jeon EK, Hong SH, Kim TH, Jung SE, Park JC, Won HS, Ko YH, Rho SY, Hong YS. Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer. Cancer Res Treat 2011;43:148-53. [PMID: 22022291 DOI: 10.4143/crt.2011.43.3.148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
615 McCulloch M, Broffman M, van der Laan M, Hubbard A, Kushi L, Abrams DI, Gao J, Colford JM Jr. Colon cancer survival with herbal medicine and vitamins combined with standard therapy in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods. Integr Cancer Ther 2011;10:240-59. [PMID: 21964510 DOI: 10.1177/1534735411406539] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
616 Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138:65-72. [PMID: 21960318 DOI: 10.1007/s00432-011-1061-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 4.8] [Reference Citation Analysis]
617 Aparo S, Goel S. Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol 2012;83:47-58. [PMID: 21944740 DOI: 10.1016/j.critrevonc.2011.08.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
618 Maurya DK, Ayuzawa R, Doi C, Troyer D, Tamura M. Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo. J Environ Pathol Toxicol Oncol 2011;30:1-10. [PMID: 21609311 DOI: 10.1615/jenvironpatholtoxicoloncol.v30.i1.10] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
619 Kambe M, Kikuchi H, Gamo M, Yoshioka T, Ohashi Y, Kanamaru R. Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. Int J Clin Oncol 2012;17:150-4. [PMID: 21786211 DOI: 10.1007/s10147-011-0272-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
620 O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381-3388. [PMID: 21788561 DOI: 10.1200/jco.2010.34.3426] [Cited by in Crossref: 300] [Cited by in F6Publishing: 321] [Article Influence: 25.0] [Reference Citation Analysis]
621 Aranda E, Abad A, Carrato A, Cervantes A, García-Foncillas J, García Alfonso P, García Carbonero R, Gómez España A, Tabernero JM, Díaz-Rubio E. Treatment recommendations for metastatic colorectal cancer. Clin Transl Oncol 2011;13:162-78. [PMID: 21421461 DOI: 10.1007/s12094-011-0636-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
622 Field KM, Kosmider S, Jefford M, Jennens R, Green M, Gibbs P. Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice? J Oncol Pract 2008;4:271-6. [PMID: 20856756 DOI: 10.1200/JOP.0852002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
623 Brown KS. Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases. Semin Intervent Radiol 2006;23:99-108. [PMID: 21326724 DOI: 10.1055/s-2006-939845] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
624 Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics 2008;2:53-9. [PMID: 19707427 DOI: 10.2147/btt.s1519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
625 Zafar SY, Marcello JE, Wheeler JL, Rowe KL, Morse MA, Herndon JE, Abernethy AP. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract 2009;5:228-33. [PMID: 20856733 DOI: 10.1200/JOP.091010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
626 Carethers JM. Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor. Therap Adv Gastroenterol 2008;1:33-42. [PMID: 21180512 DOI: 10.1177/1756283X08093607] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
627 Brouquet A, Belghiti J. Chemotherapy and its effect on liver hypertrophy: implications for portal vein embolization and resection. Semin Intervent Radiol. 2008;25:162-167. [PMID: 21326557 DOI: 10.1055/s-2008-1076682] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
628 Emmink BL, Van Houdt WJ, Vries RG, Hoogwater FJ, Govaert KM, Verheem A, Nijkamp MW, Steller EJ, Jimenez CR, Clevers H, Borel Rinkes IH, Kranenburg O. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology 2011;141:269-78. [PMID: 21459094 DOI: 10.1053/j.gastro.2011.03.052] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 5.8] [Reference Citation Analysis]
629 Lee S 2nd, Park SH, Lim DH, Park KW, Lee J, Park JO, Park YS, Lim HY, Kang WK. A retrospective study of first-line combination chemotherapy in advanced colorectal cancer: a Korean single-center experience. Cancer Res Treat 2011;43:96-101. [PMID: 21811425 DOI: 10.4143/crt.2011.43.2.96] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
630 Fakih M, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 Suppl 1:S3-17. [PMID: 20680105 DOI: 10.3747/co.v17is1.616] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
631 Tam VC, Rask S, Koru-Sengul T, Dhesy-Thind S. Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer. Curr Oncol 2009;16:13-20. [PMID: 20016742 DOI: 10.3747/co.v16i6.426] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
632 Shimura T, Kataoka H, Hirata Y, Mizushima T, Murakami K, Mabuchi M, Mizoshita T, Kubota E, Tanida S, Kamiya T, Joh T. Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy. J Gastrointest Cancer 2011;42:68-72. [PMID: 20563895 DOI: 10.1007/s12029-010-9176-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
633 Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, Baiget M. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer. 2011;105:53-57. [PMID: 21654688 DOI: 10.1038/bjc.2011.206] [Cited by in Crossref: 85] [Cited by in F6Publishing: 92] [Article Influence: 7.1] [Reference Citation Analysis]
634 Blanke CD, Bot BM, Thomas DM, Bleyer A, Kohne CH, Seymour MT, de Gramont A, Goldberg RM, Sargent DJ. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol 2011;29:2781-6. [PMID: 21646604 DOI: 10.1200/JCO.2010.33.5281] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
635 Stevenson L, Allen WL, Proutski I, Stewart G, Johnston L, McCloskey K, Wilson PM, Longley DB, Johnston PG. Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway. PLoS One 2011;6:e20276. [PMID: 21629658 DOI: 10.1371/journal.pone.0020276] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
636 Uddin S, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Jehan Z, Bavi P, Siraj AK, Al-Kuraya KS. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol 2011;178:537-47. [PMID: 21281787 DOI: 10.1016/j.ajpath.2010.10.020] [Cited by in Crossref: 101] [Cited by in F6Publishing: 112] [Article Influence: 8.4] [Reference Citation Analysis]
637 Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 2011;8:332-8. [PMID: 21611115 DOI: 10.7150/ijms.8.332] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
638 Catenacci DV, Kozloff M, Kindler HL, Polite B. Personalized colon cancer care in 2010. Semin Oncol 2011;38:284-308. [PMID: 21421118 DOI: 10.1053/j.seminoncol.2011.01.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
639 Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther 2010;14:375-84. [PMID: 21275455 DOI: 10.1007/BF03256395] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
640 Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O’Mahony MS, Maughan TS, Parmar M, Langley RE. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377:1749-1759. [PMID: 21570111 DOI: 10.1016/s0140-6736(11)60399-1] [Cited by in Crossref: 281] [Cited by in F6Publishing: 302] [Article Influence: 23.4] [Reference Citation Analysis]
641 Wang-gillam A, Lockhart AC, Picus J. Advances in Management of Metastatic Colorectal Cancer. Cancer Metastasis 2011. [DOI: 10.1017/cbo9780511976117.035] [Reference Citation Analysis]
642 Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
643 Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, Pang H, Hurwitz HI. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2011;10:210-6. [PMID: 21855046 DOI: 10.1016/j.clcc.2011.03.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
644 Ma D, Tremblay P, Mahngar K, Akbari-Asl P, Collins J, Hudlicky T, McNulty J, Pandey S. A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen. Invest New Drugs 2012;30:1012-27. [PMID: 21494837 DOI: 10.1007/s10637-011-9668-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
645 Chen LP, Lin SJ, Fu TY, Yu MS. Locally advanced female urethral adenocarcinoma of enteric origin: the role of adjuvant chemoradiation and brief review. Kaohsiung J Med Sci 2011;27:150-4. [PMID: 21463838 DOI: 10.1016/j.kjms.2010.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
646 LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011;71:3635-3648. [PMID: 21464044 DOI: 10.1158/0008-5472.can-10-2430] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 5.7] [Reference Citation Analysis]
647 Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 2011;63:184-92. [PMID: 20561951 DOI: 10.1016/j.addr.2010.05.008] [Cited by in Crossref: 174] [Cited by in F6Publishing: 151] [Article Influence: 14.5] [Reference Citation Analysis]
648 Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, Shiraishi Y, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Okamura N, Yamamori M, Tamura T, Sakaeda T. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011;8:210-5. [PMID: 21448307 DOI: 10.7150/ijms.8.210] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
649 Scartozzi M, Siquini W, Galizia E, Stortoni P, Marmorale C, Berardi R, Fianchini A, Cascinu S. The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. Dig Liver Dis 2011;43:194-8. [PMID: 20728416 DOI: 10.1016/j.dld.2010.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
650 Fernández Coimbra FJ, Pires TC, da Costa Junior WL, Diniz AL, de Castro Ribeiro HS. Advances in the surgical treatment of colorectal liver metastases. Revista da Associação Médica Brasileira (English Edition) 2011;57:215-222. [DOI: 10.1016/s2255-4823(11)70047-9] [Reference Citation Analysis]
651 Pawlik TM, Cosgrove D. The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg 2011;15:410-5. [PMID: 21253876 DOI: 10.1007/s11605-011-1423-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
652 Fernández Coimbra FJ, Pires TC, da Costa Junior WL, Diniz AL, de Castro Ribeiro HS. Advances in the surgical treatment of colorectal liver metastases. Revista da Associação Médica Brasileira 2011;57:215-222. [DOI: 10.1016/s0104-4230(11)70047-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
653 Ronnekleiv-Kelly SM, Kennedy GD. Management of stage IV rectal cancer: Palliative options. World J Gastroenterol 2011; 17(7): 835-847 [PMID: 21412493 DOI: 10.3748/wjg.v17.i7.835] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
654 García-Carbonero R, Gómez España MA, Casado Sáenz E, Alonso Orduña V, Cervantes Ruipérez A, Gallego Plazas J, García Alfonso P, Juez Martel I, González Flores E, Lomas Garrido M, Isla Casado D; SEOM (Spanish Society for Medical Oncology). SEOM clinical guidelines for the treatment of advanced colorectal cancer. Clin Transl Oncol 2010;12:729-34. [PMID: 20974564 DOI: 10.1007/s12094-010-0587-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
655 Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med. 2011;9:10. [PMID: 21281463 DOI: 10.1186/1741-7015-9-10] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
656 Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29:1083-1090. [PMID: 21263087 DOI: 10.1200/jco.2010.32.6132] [Cited by in Crossref: 276] [Cited by in F6Publishing: 303] [Article Influence: 23.0] [Reference Citation Analysis]
657 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Marusasa T, Hashiguchi T, Uchida T, Sakuyama N, Sato T, Kishine K, Futagawa S, Nagaoka I. Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer. Oncol Lett 2011;2:309-13. [PMID: 22866082 DOI: 10.3892/ol.2011.251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
658 Tsoulfas G, Pramateftakis MG, Kanellos I. Surgical treatment of hepatic metastases from colorectal cancer. World J Gastrointest Oncol 2011; 3(1): 1-9 [PMID: 21267397 DOI: 10.4251/wjgo.v3.i1.1] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
659 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
660 Lemmens VE, de Haan N, Rutten HJ, Martijn H, Loosveld OJ, Roumen RM, Creemers GJ. Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992-2008. Clin Exp Metastasis 2011;28:283-90. [PMID: 21207120 DOI: 10.1007/s10585-010-9370-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
661 Bachet J, Taïeb J, Mitry E, Rougier P. Tumeurs digestives : côlon — rectum. Thérapeutique du cancer 2011. [DOI: 10.1007/978-2-8178-0021-9_23] [Reference Citation Analysis]
662 Habib MR, Morris DL. Liver Metastases. Induction Chemotherapy 2011. [DOI: 10.1007/978-3-642-18173-3_23] [Reference Citation Analysis]
663 Huang RS, Innocenti F, Ratain MJ. Irinotecan. Pharmacogenomic Testing in Current Clinical Practice 2011. [DOI: 10.1007/978-1-60761-283-4_5] [Reference Citation Analysis]
664 Newton M, Wetzstein G, Sullivan D. Topoisomerase I Inhibitors – The Camptothecins. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures 2011. [DOI: 10.1007/978-90-481-9704-0_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
665 Takanori G, Youhei K, Katsuji S, Mitsuhiro M, Kanji K, Akio Y. Response to Modified TEGAFIRI in a Patient with Synchronous Multiple Liver Metastases of Colon Cancer. Case Rep Gastroenterol 2011;5:95-9. [PMID: 23136565 DOI: 10.1159/000324399] [Reference Citation Analysis]
666 Mclemore EC, Ramamoorthy S. Colorectal Cancer: Metastatic (Palliation). The ASCRS Textbook of Colon and Rectal Surgery 2011. [DOI: 10.1007/978-1-4419-1584-9_47] [Reference Citation Analysis]
667 Aglietta M. Preoperation Chemotherapy. Surgical Treatment of Colorectal Liver Metastases 2011. [DOI: 10.1007/978-88-470-1809-9_6] [Reference Citation Analysis]
668 Reinacher-schick A. Metastasiertes kolorektales Karzinom – State of the Art 2011. Viszeralmedizin 2011;27:445-453. [DOI: 10.1159/000335089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
669 El-shami K, Nallapareddy S, Messersmith W. Systemic Therapy for Colon Cancer. Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer 2011. [DOI: 10.1016/b978-1-4160-4686-8.50020-8] [Reference Citation Analysis]
670 Ogata Y, Tokunaga S, Emi Y, Oki E, Saeki H, Shirabe K, Hasegawa H, Sadanaga N, Samura H, Fujita F, Tanaka T, Kitazono M, Yamamoto M, Morikita T, Inomata M, Kakeji Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer. A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. Surg Today 2011;41:84-90. [PMID: 21191696 DOI: 10.1007/s00595-010-4418-6] [Reference Citation Analysis]
671 Allen WL, Jithesh PV, Oliver GR, Proutski I, Longley DB, Lenz HJ, Proutski V, Harkin P, Johnston PG. The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information. BMC Cancer 2010;10:687. [PMID: 21172019 DOI: 10.1186/1471-2407-10-687] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
672 Heong V, Ananda S, Tie J, Gibbs P. Guesstimates are not good enough for determining what is happening in routine care. Br J Cancer 2010;103:1885-6; author reply 1887-8. [PMID: 21063413 DOI: 10.1038/sj.bjc.6605998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
673 Pohl M, Reinacher-schick A, Schmiegel W. Palliative endoscopic and chemotherapeutic treatment. Eur Surg 2010;42:287-98. [DOI: 10.1007/s10353-010-0571-9] [Reference Citation Analysis]
674 Ghiringhelli F, Vincent J, Guiu B, Chauffert B, Ladoire S. Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. Invest New Drugs. 2012;30:758-764. [PMID: 21057973 DOI: 10.1007/s10637-010-9575-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
675 Bouchahda M, Macarulla T, Liedo G, Lévi F, Elez ME, Paule B, Karaboué A, Artru P, Tabernero J, Machover D, Innominato P, Goldschmidt E, Bonnet D, Ducreux M, Castagne V, Guimbaud R. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2011;28 Suppl 1:S253-8. [PMID: 21053102 DOI: 10.1007/s12032-010-9716-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
676 Folprecht G. [Current medicinal treatment of metastasized colorectal carcinoma]. Chirurg. 2010;81:507-515. [PMID: 20574792 DOI: 10.1007/s00104-010-1892-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
677 Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010;10:567. [PMID: 20958992 DOI: 10.1186/1471-2407-10-567] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
678 López R, Salgado M, Reboredo M, Grande C, Méndez JC, Jorge M, Romero C, Quintero G, de la Cámara J, Candamio S. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer 2010;103:1536-41. [PMID: 20940719 DOI: 10.1038/sj.bjc.6605938] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
679 Wilson PM, Bohanes P, Lenz H. Using The Colon Cancer Multigene Recurrence Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction? Curr Colorectal Cancer Rep 2010;6:183-192. [DOI: 10.1007/s11888-010-0064-z] [Reference Citation Analysis]
680 Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Pract Res Clin Gastroenterol 2010;24:555-71. [PMID: 20955959 DOI: 10.1016/j.bpg.2010.07.007] [Cited by in Crossref: 94] [Cited by in F6Publishing: 95] [Article Influence: 7.2] [Reference Citation Analysis]
681 Goff LW, Benson AB 3rd, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Invest New Drugs 2012;30:290-8. [PMID: 20857171 DOI: 10.1007/s10637-010-9528-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
682 Mohile SG, Kaur HP, Goldberg RM. Management of colon and rectal cancer in older adults. Practical Geriatric Oncology 2010. [DOI: 10.1017/cbo9780511763182.011] [Reference Citation Analysis]
683 Vonk DT, Hazard LJ. Do all locally advanced rectal cancers require radiation? A review of literature in the modern era. J Gastrointest Oncol 2010;1:45-54. [PMID: 22811804 DOI: 10.3978/j.issn.2078-6891.2010.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
684 Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-13. [PMID: 20951919 DOI: 10.1016/j.gtc.2010.08.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
685 Saif MW, Sellers S, Diasio RB, Douillard JY. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anticancer Drugs 2010;21:716-23. [PMID: 20581657 DOI: 10.1097/CAD.0b013e32833cb658] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
686 Dimitroulis D, Nikiteas N, Troupis T, Patsouras D, Skandalakis P, Kouraklis G. Role of surgery in colorectal liver metastases: Too early or too late? World J Gastroenterol 2010; 16(28): 3484-3490 [PMID: 20653056 DOI: 10.3748/wjg.v16.i28.3484] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
687 Tanoue Y, Tanaka N, Nomura Y. Primary site resection is superior for incurable metastatic colorectal cancer. World J Gastroenterol 2010; 16(28): 3561-3566 [PMID: 20653065 DOI: 10.3748/wjg.v16.i28.3561] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
688 Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer. 2010;103:581-589. [PMID: 20628391 DOI: 10.1038/sj.bjc.6605776] [Cited by in Crossref: 64] [Cited by in F6Publishing: 73] [Article Influence: 4.9] [Reference Citation Analysis]
689 Wang J, Zhang Y, Hou Y, Li J, He X. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.cd008593] [Reference Citation Analysis]
690 Gao F, Cao Y, Liao C, Mo Z, Tan A; Cochrane Colorectal Cancer Group. Sequential versus combination chemotherapy for advanced colorectal cancer. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd008594] [Reference Citation Analysis]
691 Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16(25): 3133-3143 [PMID: 20593498 DOI: 10.3748/wjg.v16.i25.3133] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 91] [Article Influence: 6.1] [Reference Citation Analysis]
692 Komatsu Y, Yuki S, Fuse N, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Sakata Y, Asaka M. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. Adv Ther 2010;27:483-92. [PMID: 20559897 DOI: 10.1007/s12325-010-0037-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
693 Ripley RT, Davis JL, Kemp CD, Steinberg SM, Toomey MA, Avital I. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. Trials. 2010;11:62. [PMID: 20500867 DOI: 10.1186/1745-6215-11-62] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
694 Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol. 2010;69:58-66. [PMID: 20078613 DOI: 10.1111/j.1365-2125.2009.03556.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 5.8] [Reference Citation Analysis]
695 Gangadhar T, Schilsky RL. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010;7:318-325. [PMID: 20440283 DOI: 10.1038/nrclinonc.2010.62] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
696 Mashiko S, Nagaoka I, Kitajima M, Watanabe T, Nishimura K, Futagawa S, Ochiai T. Evaluation of serum iron levels during FOLFOX4 and FOLFIRI therapies. Exp Ther Med 2010;1:507-11. [PMID: 22993568 DOI: 10.3892/etm_00000080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
697 Elhjouji A, Ait Ali A, El Khader A, Baba H, Alahyane A, Oueldjeddou C, El fahssi M, Sair K, Zentar A. Métastases hépatiques des cancers colorectaux : intérêt du traitement d’induction dans l’optimisation des résections. À propos de neuf cas. J Afr Cancer 2010;2:67-71. [DOI: 10.1007/s12558-010-0078-4] [Reference Citation Analysis]
698 Gomez D, Cameron IC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford) 2010;12:227-38. [PMID: 20590892 DOI: 10.1111/j.1477-2574.2010.00158.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
699 Louvet C, André T, Gamelin E, Hebbar M, Mabro M, Bennamoun M, Rassam H, de Gramont A. Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer. J Oncol 2010;2010:785934. [PMID: 20396391 DOI: 10.1155/2010/785934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
700 Zeino Z, Sisson G, Bjarnason I. Adverse effects of drugs on small intestine and colon. Best Pract Res Clin Gastroenterol 2010;24:133-41. [PMID: 20227027 DOI: 10.1016/j.bpg.2010.02.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
701 Kurkjian C, Kummar S. Advances in the Treatment of Metastatic Colorectal Cancer. Disease-a-Month 2010;56:187-203. [DOI: 10.1016/j.disamonth.2009.12.005] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
702 Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics 2009;10:1139-46. [PMID: 19604089 DOI: 10.2217/pgs.09.35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
703 Yukisawa S, Fujiwara Y, Yamamoto Y, Ueno T, Matsueda K, Kohno A, Suenaga M. Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients. Br J Radiol 2010;83:850-3. [PMID: 20223904 DOI: 10.1259/bjr/41019720] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
704 Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. Interaction of tumour biology and tumour burden in determining outcome after hepatic resection for colorectal metastases. HPB (Oxford) 2010;12:84-93. [PMID: 20495651 DOI: 10.1111/j.1477-2574.2009.00127.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
705 Watkins DJ, Chau I, Cunningham D, Mudan SS, Karanjia N, Brown G, Ashley S, Norman AR, Gillbanks A. Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. Br J Cancer 2010;102:255-61. [PMID: 20087355 DOI: 10.1038/sj.bjc.6605508] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
706 Kurkjian C, Kummar S. Advances in the treatment of metastatic colorectal cancer. Am J Ther 2009;16:412-20. [PMID: 19955859 DOI: 10.1097/MJT.0b013e3181907ed9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
707 Dickson MA, Shah MA, Rathkopf D, Tse A, Carvajal RD, Wu N, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol 2010;66:1113-21. [PMID: 20953860 DOI: 10.1007/s00280-010-1269-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
708 Ying-Liu, Bing-Liang, Liu WJ, Wang JF, Fan QX. Combined chemotherapy with irinotecan and nedaplatin as a second-line regimen for patients with advanced esophageal squamous cell carcinoma: a report of 24 cases. Shijie Huaren Xiaohua Zazhi 2010; 18(3): 298-302 [DOI: 10.11569/wcjd.v18.i3.298] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
709 Comella P, Casaretti R, Manzo R, Sandomenico C, Licenziato M, Avallone A, Franco L; Southern Italy Cooperative Oncology Group Investigators. Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet. Acta Oncol 2010;49:50-6. [PMID: 20100144 DOI: 10.3109/02841860903369540] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
710 Bélanger AS, Tojcic J, Harvey M, Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Mol Biol 2010;11:9. [PMID: 20096102 DOI: 10.1186/1471-2199-11-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 4.2] [Reference Citation Analysis]
711 Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol 2010; 2(1): 19-30 [PMID: 21160813 DOI: 10.4251/wjgo.v2.i1.19] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
712 Díaz R, Aparicio J, Molina J, Palomar L, Giménez A, Ponce J, Segura A, Gómez-Codina J. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol 2006;23:347-57. [PMID: 17018892 DOI: 10.1385/mo:23:3:347] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
713 Matsui T, Kojima H, Fujii Y, Yamada T, Hirota M, Uemura T, Fujimitsu Y, Sakamoto J. Appropriate interruption of cetuximab may balance efficacy and toxicity: a case of long-term treatment with FOLFIRI plus cetuximab. Ann Cancer Res Therap 2010;18:73-76. [DOI: 10.4993/acrt.18.73] [Reference Citation Analysis]
714 Petrovic T, Majdevac I, Budisin N, Radovanovic Z, Nikolic I, Nikin Z, Gavrancic B, Mihailovic J. The results of surgical treatment of metastatic liver tumor. Arch Oncol 2010;18:14-16. [DOI: 10.2298/aoo1002014p] [Reference Citation Analysis]
715 Folprecht G, Bokemeyer C, Stahl M, Heinemann V, Stemmler H, Wolf M. Chemotherapie und systemische Therapie bei Lebermetastasen. Hepatobiliäre und Pankreastumoren 2010. [DOI: 10.1007/978-3-642-04935-4_40] [Reference Citation Analysis]
716 Field KM, Zalcberg JR. Chemotherapy: Metastatic Disease. Rectal Cancer 2010. [DOI: 10.1007/978-1-60761-567-5_12] [Reference Citation Analysis]
717 sei M, sei M, sei M, sei M, sei M, sei M, sei M. In vitro Evaluation of Anticancer Effects of FOLFIRI and mFOLFOX 6 Chemotherapy Regimens and Their Effects on EGFR Expression. Jpn J Pharm Health Care Sci 2010;36:855-862. [DOI: 10.5649/jjphcs.36.855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
718 Al-sukhni E, Gallinger S. Treatment of Colorectal Cancer. Metastasis of Colorectal Cancer 2010. [DOI: 10.1007/978-90-481-8833-8_13] [Reference Citation Analysis]
719 Harasym TO, Liboiron BD, Mayer LD. Drug Ratio-Dependent Antagonism: A New Category of Multidrug Resistance and Strategies for Its Circumvention. Methods in Molecular Biology 2010. [DOI: 10.1007/978-1-60761-416-6_13] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
720 Bredin C, Massoure M, Corberand D, Rey P. Complications digestives des chimiothérapies. EMC - Gastro-entérologie 2010;5:1-15. [DOI: 10.1016/s1155-1968(10)19795-8] [Reference Citation Analysis]
721 Dancygier H, Strassburg CP. Hepatic Drug Metabolism and Drug Toxicity. Clinical Hepatology 2010. [DOI: 10.1007/978-3-642-04519-6_38] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
722 Thermann P, Seufferlein T. Aktuelle Therapie des Kolonkarzinoms. Gastroenterologe 2010;5:57-71. [DOI: 10.1007/s11377-009-0387-y] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
723 Inoue Y, Tanaka K, Hiro J, Toiyama Y, Miki C, Kusunoki M. Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer. Oncol Lett 2010;1:81-5. [PMID: 22966260 DOI: 10.3892/ol_00000014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
724 Ferraldeschi R. Pharmacogenetics in Colorectal Cancer. Pharmacogenetics: Making cancer treatment safer and more effective 2010. [DOI: 10.1007/978-90-481-8618-1_5] [Reference Citation Analysis]
725 Nikapota AD, Harrison M, Glynne-jones R. Chemotherapy Trials for Colorectal Cancer in Advanced Disease: What’s the Current Hypothesis? Coloproctology 2010. [DOI: 10.1007/978-1-84882-756-1_4] [Reference Citation Analysis]
726 Bresalier RS. Colorectal Cancer. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2010. [DOI: 10.1016/b978-1-4160-6189-2.00123-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
727 Hong YS, Kim TW. Chemotherapy for Colorectal Cancer. J Korean Med Assoc 2010;53:582. [DOI: 10.5124/jkma.2010.53.7.582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
728 Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:866-71. [PMID: 20038727 DOI: 10.1200/JCO.2009.23.6125] [Cited by in Crossref: 130] [Cited by in F6Publishing: 140] [Article Influence: 9.3] [Reference Citation Analysis]
729 Yim KL, Cunningham D. Chemotherapy: Optimizing irinotecan regimens for colorectal cancer. Nat Rev Clin Oncol 2009;6:560-1. [PMID: 19786997 DOI: 10.1038/nrclinonc.2009.140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
730 Cao D, Hou M, Guan YS, Jiang M, Yang Y, Gou HF. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009;9:432. [PMID: 20003271 DOI: 10.1186/1471-2407-9-432] [Cited by in Crossref: 129] [Cited by in F6Publishing: 141] [Article Influence: 9.2] [Reference Citation Analysis]
731 Marshall JL. Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism? J Oncol 2009;2009:937305. [PMID: 20016807 DOI: 10.1155/2009/937305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
732 Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, Laan AC, Schott S, Losekoot N, Honeywell RJ, Peters GJ. Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine. Invest New Drugs 2011;29:248-57. [PMID: 19957099 DOI: 10.1007/s10637-009-9353-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
733 Folprecht G, Bokemeyer C, Weitz J. Therapie des metastasierten Kolonkarzinoms. Onkologe 2009;15:1223-1234. [DOI: 10.1007/s00761-009-1723-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
734 LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2009;2:67. [PMID: 19948057 DOI: 10.1186/1755-8794-2-67] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 4.9] [Reference Citation Analysis]
735 Byström P, Björkegren K, Larsson A, Johansson L, Berglund A. Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer. Ups J Med Sci 2009;114:160-4. [PMID: 19736606 DOI: 10.1080/03009730903027172] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
736 Yoshioka T, Kato S, Gamoh M, Chiba N, Suzuki T, Sakayori N, Kato S, Shibata H, Shimodaira H, Otsuka K, Kakudo Y, Takahashi S, Ishioka C. Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Br J Cancer 2009;101:1972-7. [PMID: 19920821 DOI: 10.1038/sj.bjc.6605432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
737 Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009;14:4517-45. [PMID: 19924084 DOI: 10.3390/molecules14114517] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 5.2] [Reference Citation Analysis]
738 Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol. 2009;6:687-697. [PMID: 19884901 DOI: 10.1038/nrclinonc.2009.165] [Cited by in Crossref: 73] [Cited by in F6Publishing: 79] [Article Influence: 5.2] [Reference Citation Analysis]
739 Tanaka K, Matsuyama R, Takeda K, Matsuo K, Nagano Y, Endo I. Aggressive liver resection including major-vessel resection for colorectal liver metastases. World J Hepatol 2009; 1(1): 79-89 [PMID: 21160969 DOI: 10.4254/wjh.v1.i1.79] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
740 Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, Stemmler HJ. UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol 2009; 15(40): 5058-5066 [PMID: 19859999 DOI: 10.3748/wjg.15.5058] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
741 Koizumi W, Boku N, Yamaguchi K, Miyata Y, Sawaki A, Kato T, Toh Y, Hyodo I, Nishina T, Furuhata T. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2010;21:766-771. [PMID: 19828562 DOI: 10.1093/annonc/mdp371] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
742 Takakura Y, Ikeda S, Yoshimitsu M, Hinoi T, Sumitani D, Takeda H, Kawaguchi Y, Shimomura M, Tokunaga M, Okajima M, Ohdan H. Retroperitoneal abscess complicated with necrotizing fasciitis of the thigh in a patient with sigmoid colon cancer. World J Surg Oncol 2009;7:74. [PMID: 19811627 DOI: 10.1186/1477-7819-7-74] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
743 Grothey A, Sargent DJ. Reply to F. Montagnani et al. JCO 2009;27:e134-e135. [DOI: 10.1200/jco.2009.23.3114] [Reference Citation Analysis]
744 Yang XC, Tu CX, Luo PH, Zhu H, Zhu DF, Wu HH, Zhou XL, Lu W, He QJ, Yang B. Antimetastatic activity of MONCPT in preclinical melanoma mice model. Invest New Drugs 2010;28:800-11. [PMID: 19789842 DOI: 10.1007/s10637-009-9323-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
745 Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
746 Ghiringhelli F, Guiu B, Chauffert B, Ladoire S. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World J Gastroenterol 2009; 15(34): 4278-4283 [PMID: 19750570 DOI: 10.3748/wjg.15.4278] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
747 Garcia-Alfonso P, Muñoz-Martin A, Mendez-Ureña M, Quiben-Pereira R, Gonzalez-Flores E, Perez-Manga G. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer 2009;101:1039-43. [PMID: 19738605 DOI: 10.1038/sj.bjc.6605261] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
748 Stec R, Bodnar L, Szczylik C. Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. J Cancer Res Clin Oncol 2010;136:283-92. [PMID: 19693536 DOI: 10.1007/s00432-009-0660-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
749 Abdalla EK. Surgical management of colorectal liver metastases. Community Oncology 2009;6:349-357. [DOI: 10.1016/s1548-5315(11)70258-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
750 Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246. [PMID: 19619339 DOI: 10.1186/1471-2407-9-246] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
751 Shiroiwa T, Fukuda T, Tsutani K. Health utility scores of colorectal cancer based on societal preference in Japan. Qual Life Res 2009;18:1095-103. [PMID: 19626462 DOI: 10.1007/s11136-009-9513-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
752 Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009;229:126-44. [PMID: 19426219 DOI: 10.1111/j.1600-065X.2009.00771.x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 196] [Article Influence: 12.6] [Reference Citation Analysis]
753 Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009;6:207-218. [PMID: 19333227 DOI: 10.1038/nrclinonc.2009.16] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
754 Abad A, Massuti B, Antón A, Vega ME, Yuste AL, Marcuello E, Manzano JL, Alonso V, Carrato A, Martinez-Villacampa M, Tabernero J, Aranda E, Rivera F, Díaz-Rubio E; Spanish Cooperative Group for Digestive Tumor Therapy. Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Fina